<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article
  PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" dtd-version="3.0" xml:lang="en">
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">PLoS ONE</journal-id>
<journal-id journal-id-type="publisher-id">plos</journal-id>
<journal-id journal-id-type="pmc">plosone</journal-id><journal-title-group>
<journal-title>PLoS ONE</journal-title></journal-title-group>
<issn pub-type="epub">1932-6203</issn>
<publisher>
<publisher-name>Public Library of Science</publisher-name>
<publisher-loc>San Francisco, USA</publisher-loc></publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="publisher-id">PONE-D-13-39928</article-id>
<article-id pub-id-type="doi">10.1371/journal.pone.0090135</article-id>
<article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="Discipline-v2"><subject>Biology</subject><subj-group><subject>Genetics</subject><subj-group><subject>Cancer genetics</subject></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v2"><subject>Medicine</subject><subj-group><subject>Clinical research design</subject><subj-group><subject>Meta-analyses</subject><subject>Systematic reviews</subject></subj-group></subj-group><subj-group><subject>Drugs and devices</subject><subj-group><subject>Adverse reactions</subject></subj-group></subj-group><subj-group><subject>Oncology</subject><subj-group><subject>Cancer treatment</subject><subj-group><subject>Antiangiogenesis therapy</subject></subj-group></subj-group><subj-group><subject>Basic cancer research</subject><subject>Oncology agents</subject></subj-group></subj-group></subj-group></article-categories>
<title-group>
<article-title>Risks of Proteinuria Associated with Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitors in Cancer Patients: A Systematic Review and Meta-Analysis</article-title>
<alt-title alt-title-type="running-head">Proteinuria Associated with VEGFR-TKIs</alt-title>
</title-group>
<contrib-group>
<contrib contrib-type="author" equal-contrib="yes" xlink:type="simple"><name name-style="western"><surname>Zhang</surname><given-names>Ze-Feng</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib>
<contrib contrib-type="author" equal-contrib="yes" xlink:type="simple"><name name-style="western"><surname>Wang</surname><given-names>Tao</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="corresp" rid="cor1"><sup>*</sup></xref></contrib>
<contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Liu</surname><given-names>Li-Hua</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib>
<contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Guo</surname><given-names>Hui-Qin</given-names></name><xref ref-type="aff" rid="aff3"><sup>3</sup></xref></contrib>
</contrib-group>
<aff id="aff1"><label>1</label><addr-line>Department of Thoracic Surgery, Fourth Affiliated Hospital of Hebei Medical University, Shijiazhuang, People's Republic of China</addr-line></aff>
<aff id="aff2"><label>2</label><addr-line>Department of Biological therapy, Fourth Affiliated Hospital of Hebei Medical University, Shijiazhuang, People's Republic of China</addr-line></aff>
<aff id="aff3"><label>3</label><addr-line>Department of Pathology, Cancer institute and Hospital Chinese Academi of Medical Sciences and Peking Union Medical College, Beijing, People's Republic of China</addr-line></aff>
<contrib-group>
<contrib contrib-type="editor" xlink:type="simple"><name name-style="western"><surname>Lafrenie</surname><given-names>Robert</given-names></name>
<role>Editor</role>
<xref ref-type="aff" rid="edit1"/></contrib>
</contrib-group>
<aff id="edit1"><addr-line>Sudbury Regional Hospital, Canada</addr-line></aff>
<author-notes>
<corresp id="cor1">* E-mail: <email xlink:type="simple">wangtao130928@163.com</email></corresp>
<fn fn-type="conflict"><p>The authors have declared that no competing interests exist.</p></fn>
<fn fn-type="con"><p>Conceived and designed the experiments: ZFZ TW. Performed the experiments: ZFZ LHL HQG. Analyzed the data: ZFZ TW. Contributed reagents/materials/analysis tools: ZFZ LHL HQG. Wrote the paper: ZFZ TW.</p></fn>
</author-notes>
<pub-date pub-type="collection"><year>2014</year></pub-date>
<pub-date pub-type="epub"><day>12</day><month>3</month><year>2014</year></pub-date>
<volume>9</volume>
<issue>3</issue>
<elocation-id>e90135</elocation-id>
<history>
<date date-type="received"><day>30</day><month>9</month><year>2013</year></date>
<date date-type="accepted"><day>28</day><month>1</month><year>2014</year></date>
</history>
<permissions>
<copyright-year>2014</copyright-year>
<copyright-holder>Zhang et al</copyright-holder><license xlink:type="simple"><license-p>This is an open-access article distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/" xlink:type="simple">Creative Commons Attribution License</ext-link>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</license-p></license></permissions>
<abstract><sec>
<title>Background</title>
<p>Vascular endothelial growth factor tyrosine-kinase inhibitors (VEGFR-TKIs) have emerged as an effective targeted therapy in the treatment of cancer patients, the overall incidence and risk of proteinuria associated these drugs is unclear. We performed a systematic review and meta-analysis of published clinical trials to quantify the incidence and risk of proteinuria associated with VEGFR-TKIs.</p>
</sec><sec>
<title>Methodology</title>
<p>Databases from PubMed, Web of Science and abstracts presented at ASCO meeting up to May 31, 2013 were searched to identify relevant studies. Eligible studies included prospective phase II and III trials evaluating VEGFR-TKIs in cancer patients with adequate data on proteinuria. Statistical analyses were conducted to calculate the summary incidence, Odds ratio (OR) and 95% confidence intervals (<italic>CI</italic>s) by using either random effects or fixed effect models according to the heterogeneity of included studies.</p>
</sec><sec>
<title>Principal Findings</title>
<p>A total of 6,882 patients with a variety of solid tumors from 33 clinical trials were included in our analysis. The incidence of all-grade and high-grade (grade 3 or higher) proteinuria was 18.7% (95% CI, 13.3%–25.6%) and 2.4% (95% CI, 1.6%–3.7%), respectively. Patients treated with VEGFR-TKIs had a significantly increased risk of all-grade (OR 2.92, 95%CI: 1.09–7.82, <italic>p</italic> = <italic>0.033</italic>) and high-grade proteinuria (OR 1.97, 95%CI: 1.01–3.84, <italic>p</italic> = <italic>0.046</italic>) when compared to patients treated with control medication. No evidence of publication bias was observed.</p>
</sec><sec>
<title>Conclusions</title>
<p>The use of VEGFR-TKIs is associated with a significant increased risk of developing proteinuria. Physicians should be aware of this adverse effect and should monitor cancer patients receiving VEGFR-TKIs.</p>
</sec></abstract>
<funding-group><funding-statement>The authors have no funding or support to report.</funding-statement></funding-group><counts><page-count count="10"/></counts></article-meta>
</front>
<body><sec id="s1">
<title>Introduction</title>
<p>Angiogenesis plays an important role in the growth, invasion, and metastasis of malignancies <xref ref-type="bibr" rid="pone.0090135-Folkman1">[1]</xref>–<xref ref-type="bibr" rid="pone.0090135-Zetter1">[5]</xref>, and this process is mainly driven by vascular epithelial growth factor (VEGF). During the past decades, angiogenesis inhibitors targeting VEGF signaling pathway are the furthest along in clinical development <xref ref-type="bibr" rid="pone.0090135-Carmeliet1">[6]</xref>–<xref ref-type="bibr" rid="pone.0090135-Carmeliet2">[8]</xref>. Indeed, therapies that inhibit the VEGF pathway, including VEGF monoclonal antibody bevacizumab and vascular epithelial growth factor receptor tyrosine kinase inhibitors (VEGFR-TKIs) such as sorafenib, sunitinib, vandetanib, pazopanib axitinib, and regorafenib, have shown clinical efficacy in the treatment of several malignancies and have been approved for use in cancer treatments by regulatory agencies <xref ref-type="bibr" rid="pone.0090135-Aghajanian1">[9]</xref>–<xref ref-type="bibr" rid="pone.0090135-Raymond1">[17]</xref>.</p>
<p>However, as with many therapeutic agents, significant side effects are associated with VEGF-targeted agents, including thrombosis, bleeding, hypertension, gastrointestinal perforation and renal toxicity <xref ref-type="bibr" rid="pone.0090135-Scappaticci1">[18]</xref>–<xref ref-type="bibr" rid="pone.0090135-Sonpavde1">[35]</xref>. Proteinuria is the predominant renal toxicities. Two previous meta-analyses have demonstrated that the use of bevacizumab is associated with a significantly increased risk of developing all-grade (RR, 1.4 with low-dose bevacizumab; 95% confidence interval [CI], 1.1 to 1.7; RR, 2.2 with high dose; 95% CI, 1.6 to 2.9) and high-grade proteinuria (RR, 4.79; 95% CI 2.71 to 8.46) in comparison with controls <xref ref-type="bibr" rid="pone.0090135-Zhu1">[19]</xref>, <xref ref-type="bibr" rid="pone.0090135-Wu2">[36]</xref>. Additionally, there is evidence that proteinuria is most probably related to the pharmacological action of VEGF-targeted drugs: the inhibition of the VEGF pathway <xref ref-type="bibr" rid="pone.0090135-LaunayVacher1">[37]</xref>. Thus proteinuria may also occur with VEGFR-TKIs, which also target the VEGF signal pathway. Indeed, proteinuria associated with VEGFR-TKIs has been reported with a substantial variation in the incidences, ranging from 1.9 to 57.8% in clinical trials <xref ref-type="bibr" rid="pone.0090135-Hsu1">[38]</xref>, <xref ref-type="bibr" rid="pone.0090135-Tomita1">[39]</xref>. Moreover, a recent abstract presented at 2013 American Society of Clinical Oncology (ASCO) conference shows that the use of axitinib is associated with a significantly increased risk of developing high-grade proteinuria <xref ref-type="bibr" rid="pone.0090135-Kuei1">[40]</xref>. However, the overall incidence and risk of proteinuria with other VEGFR-TKIs has not yet to be systematically defined. Therefore, we conducted a systematic review of the literature to identify prospective clinical trials of VEGFR-TKIs and performed a meta-analysis of the published results to estimate the incidence and risk of developing proteinuria.</p>
</sec><sec id="s2" sec-type="methods">
<title>Methods</title>
<sec id="s2a">
<title>Data sources</title>
<p>Study was conducted according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement <xref ref-type="bibr" rid="pone.0090135-Moher1">[41]</xref>, <xref ref-type="bibr" rid="pone.0090135-Moher2">[42]</xref> (see <xref ref-type="supplementary-material" rid="pone.0090135.s001">Checklist S1</xref>). We searched the Pubmed (data from 1990 to May 2013) for relevant trials. Key words were sorafenib, nexavar, BAY43-9006, sunitinib, sutent, SU11248, pazopanib, votrient, GW786034, vandetanib, caprelsa, ZD6474, axitinib, AG-013736, cediranib, AZD2171, tivozanib, regorafenib, Linifanib, ABT-869, clinical trials and cancer. The search was limited to prospective clinical trials published in English. The search strategy also used text terms such as angiogenesis inhibitors and vascular endothelial growth factor receptor-tyrosine kinase inhibitors to identify relevant information. We also performed independent searches using Web of Science databases between January 1, 1990, and May 31, 2013, to ensure that no clinical trials were overlooked. Additionally, we searched the clinical trial registration website (<ext-link ext-link-type="uri" xlink:href="http://www.ClinicalTrials.gov" xlink:type="simple">http://www.ClinicalTrials.gov</ext-link>) to obtain information on the registered prospective trials. We also searched abstracts and virtual meeting presentations from the American Society of Clinical Oncology (<ext-link ext-link-type="uri" xlink:href="http://www.asco.org/ASCO" xlink:type="simple">http://www.asco.org/ASCO</ext-link>) conferences that took place between Jan 2004 and Jan 2013. Each publication was reviewed and in cases of duplicate publication only the most complete, recent, and updated report of the clinical trial was included in the meta-analysis</p>
</sec><sec id="s2b">
<title>Study Selection</title>
<p>The primary goal of our study was to determine the overall incidence of proteinuria associated with VEGFR-TKIs and establish the association between treatments with VEGFR-TKIs and the risk of developing proteinuria. Thus, only prospective phase II and III trials evaluating VEGFR-TKIs in cancer patients with adequate data on proteinuria were incorporated in the analysis. Phase I trials were omitted due to multiple dose level and limited sample sizes. Clinical trials that met the following criteria were included: (1) prospective phase 2 or 3 trials involving cancer patients; (2) participants assigned to treatment with VEGFR-TKIs (alone or in combination at any dosage or frequency); and (3) available data regarding events or incidence of proteinuria and sample size.</p>
</sec><sec id="s2c">
<title>Data Extraction and Clinical End Point</title>
<p>Data abstraction was conducted independently by two investigators, and any discrepancy between the reviewers was resolved by consensus. For each study, the following information was extracted: first author's name, year of publication, trial phase, number of enrolled subjects, treatment arms, number of patients in treatment and controlled groups, underlying malignancy, median age, median treatment duration, median progression-free survival, adverse outcomes of interest (proteinuria), name and dosage of the VEGFR-TKIs agents. Proteinuria in these studies were assessed and recorded according to the National Cancer Institute's common terminology criteria for adverse events (version2 or 3), which had been widely used in cancer clinical trials <xref ref-type="bibr" rid="pone.0090135-NCI1">[43]</xref>. Major differences between the two versions included a particular category for proteinuria in version 3, which included grade 1–5 (<xref ref-type="table" rid="pone-0090135-t001">table 1</xref>). For this study, we simply separated proteinuria into all grades and high-grade (grade 3–5) for our analysis.</p>
<table-wrap id="pone-0090135-t001" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0090135.t001</object-id><label>Table 1</label><caption>
<title>National Cancer Institute' toxicity grading criteria version 2 and 3 for proteinuria.</title>
</caption><alternatives><graphic id="pone-0090135-t001-1" position="float" mimetype="image" xlink:href="info:doi/10.1371/journal.pone.0090135.t001" xlink:type="simple"/>
<table><colgroup span="1"><col align="left" span="1"/><col align="center" span="1"/></colgroup>
<thead>
<tr>
<td align="left" rowspan="1" colspan="1">Grade</td>
<td align="left" rowspan="1" colspan="1">Version 2 or 3</td>
</tr>
</thead>
<tbody>
<tr>
<td align="left" rowspan="1" colspan="1">1</td>
<td align="left" rowspan="1" colspan="1">Dipstick 1+ or 0.15 to 1.00 g/24 h</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">2</td>
<td align="left" rowspan="1" colspan="1">Dipstick 2+ to 3+ or 1.0 to 3.5 g/24 h</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">3</td>
<td align="left" rowspan="1" colspan="1">Dipstick 4+ or &gt;3.5 g/24 h</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">4</td>
<td align="left" rowspan="1" colspan="1">Nephritic syndrome</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">5</td>
<td align="left" rowspan="1" colspan="1">Version 2 none; version 3 death</td>
</tr>
</tbody>
</table>
</alternatives></table-wrap></sec><sec id="s2d">
<title>Statistical Analysis</title>
<p>For the calculation of incidence, trials assigning patients to the treatment with VEGFR-TKIs as a single agent were used to define the incidence of proteinuria related to VEGFR-TKIs alone. The proportion of patients with proteinuria and 95% confidence interval (CI) were derived for each study. To calculate odds ratio (OR), patients assigned to VEGFR-TKIs were compared only with those assigned to control treatment in the same trial. We used the Peto method to calculate odds ratio (ORs) and 95%CI confidence intervals (CIs) of high-grade proteinuria because this method provides the best confidence interval coverage and is more powerful and relatively less biased than the fixed or random-effects analysis when dealing with low event rates <xref ref-type="bibr" rid="pone.0090135-Sweeting1">[44]</xref>. Between-study heterogeneity was estimated using the χ<sup>2</sup>-based Q statistic <xref ref-type="bibr" rid="pone.0090135-Zintzaras1">[45]</xref>. Heterogeneity was considered statistically significant when <italic>P</italic><sub>heterogeneity</sub>&lt;0.1. If heterogeneity existed, data was analyzed using a random effects model. In the absence of heterogeneity, a fixed effects model was used. A statistical test with a <italic>p</italic>-value less than 0.05 was considered significant. For comparing the incidence difference among difference tumor types and VEGFR-TKIs, we calculate the relative risk (RR) of proteinuria with RCC and other VEGFR-TKIs by using incidence of proteinuria with non-RCC or sorafenib as controls. The quantitative 5-point Jadad scale was used to assess the quality of included trials based on the reporting of the studies' methods and results <xref ref-type="bibr" rid="pone.0090135-Moher3">[46]</xref>. We then performed sub-group analysis based on the quality of included trials: low quality (≤3) versus high quality (&gt;3). The presence of publication bias was evaluated by using the Begg and Egger tests <xref ref-type="bibr" rid="pone.0090135-Yusuf1">[47]</xref>, <xref ref-type="bibr" rid="pone.0090135-Begg1">[48]</xref>. All statistical analyses were performed by using Version 2 of the Comprehensive MetaAnalysis program (Biostat, Englewood, NJ) and Open Meta-Analyst software version 4.16.12 (Tufts University).</p>
</sec></sec><sec id="s3">
<title>Results</title>
<sec id="s3a">
<title>Study selection and characteristics</title>
<p>A total of 883 potentially relevant studies were retrieved electronically, 851 of which were excluded for the reasons shown in <xref ref-type="fig" rid="pone-0090135-g001">figure 1</xref>. The remaining 32 trials were included in the review. One additional conference abstract was located as a result of hand searching. Finally, a total of 33 publications were therefore included in the review. The baseline characteristics of each trial are presented in <xref ref-type="table" rid="pone-0090135-t002">Table 2</xref>. A total of 6882 patients were available for the meta-analysis. According to the inclusion criteria of each trial, patients were required to have an adequate renal, hepatic and hematologic function. Underlying malignancies included breast cancer <xref ref-type="bibr" rid="pone.0090135-Mayer1">[49]</xref>, renal cell carcinoma <xref ref-type="bibr" rid="pone.0090135-Tomita1">[39]</xref>, <xref ref-type="bibr" rid="pone.0090135-Rixe1">[50]</xref>–<xref ref-type="bibr" rid="pone.0090135-Sternberg2">[59]</xref>, thyroid cancer <xref ref-type="bibr" rid="pone.0090135-Bible1">[60]</xref>–<xref ref-type="bibr" rid="pone.0090135-Wells2">[62]</xref>, pancreatic cancer <xref ref-type="bibr" rid="pone.0090135-Spano1">[63]</xref>, <xref ref-type="bibr" rid="pone.0090135-Kindler1">[64]</xref>, soft tissue sarcoma <xref ref-type="bibr" rid="pone.0090135-Sleijfer1">[65]</xref>, <xref ref-type="bibr" rid="pone.0090135-vanderGraaf1">[66]</xref>, glioblastoma <xref ref-type="bibr" rid="pone.0090135-Batchelor1">[67]</xref>, <xref ref-type="bibr" rid="pone.0090135-Iwamoto1">[68]</xref>, hepatocellular carcinoma <xref ref-type="bibr" rid="pone.0090135-Hsu1">[38]</xref>, <xref ref-type="bibr" rid="pone.0090135-Toh1">[69]</xref>, small-cell lung cancer <xref ref-type="bibr" rid="pone.0090135-Ramalingam1">[70]</xref>, ovarian cancer <xref ref-type="bibr" rid="pone.0090135-Robinson1">[71]</xref>, nasopharyngeal carcinoma <xref ref-type="bibr" rid="pone.0090135-Lim1">[72]</xref>, non-small-cell lung cancer <xref ref-type="bibr" rid="pone.0090135-Tan1">[73]</xref>, malignant mesothelioma <xref ref-type="bibr" rid="pone.0090135-Campbell1">[74]</xref>, alveolar soft part sarcoma <xref ref-type="bibr" rid="pone.0090135-Kummar1">[75]</xref> and colorectal cancer <xref ref-type="bibr" rid="pone.0090135-Schmoll1">[76]</xref>–<xref ref-type="bibr" rid="pone.0090135-Infante1">[79]</xref>. The median Jadad score of the fourteen randomized controlled trials was 3: five of them had Jadad scores of 5 which mentioned the concealment of allocation clearly in the randomization process, and provided the number of patients who withdrew from the trials. One trial did not mention the method for randomization process, thus had Jadad scores of 4. And six trials, did not mention the method for randomization and blinding of allocation clearly in the randomization process, thus had Jadad scores of 3. Another two trials had Jadad scores of 2.</p>
<fig id="pone-0090135-g001" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0090135.g001</object-id><label>Figure 1</label><caption>
<title>Selection process for clinical trials included in the meta-analysis.</title>
</caption><graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pone.0090135.g001" position="float" xlink:type="simple"/></fig><table-wrap id="pone-0090135-t002" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0090135.t002</object-id><label>Table 2</label><caption>
<title>Baseline characteristics of the 33 trials included in the meta-analysis (n = 6882).</title>
</caption><alternatives><graphic id="pone-0090135-t002-2" position="float" mimetype="image" xlink:href="info:doi/10.1371/journal.pone.0090135.t002" xlink:type="simple"/>
<table><colgroup span="1"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/></colgroup>
<thead>
<tr>
<td align="left" rowspan="1" colspan="1">Authors/year/phase</td>
<td align="left" rowspan="1" colspan="1">Histology</td>
<td align="left" rowspan="1" colspan="1">Patients enrolled</td>
<td align="left" rowspan="1" colspan="1">Treatment Arm</td>
<td align="left" rowspan="1" colspan="1">Median age (years)</td>
<td align="left" rowspan="1" colspan="1">Median treatment duration (months)</td>
<td align="left" rowspan="1" colspan="1">Median PFS/TTP (months)</td>
<td align="left" rowspan="1" colspan="1">Median OS (months)</td>
<td align="left" rowspan="1" colspan="1">No. for analysis</td>
<td align="left" rowspan="1" colspan="1">No. of high-grade proteinuria</td>
<td align="left" rowspan="1" colspan="1">Jadad score</td>
</tr>
</thead>
<tbody>
<tr>
<td align="left" rowspan="1" colspan="1"><bold>Rixe O. et al/2007/II</bold></td>
<td align="left" rowspan="1" colspan="1">RCC</td>
<td align="left" rowspan="1" colspan="1">52</td>
<td align="left" rowspan="1" colspan="1">Axitinib 5 mg bid po</td>
<td align="left" rowspan="1" colspan="1">59</td>
<td align="left" rowspan="1" colspan="1">9.4</td>
<td align="left" rowspan="1" colspan="1">15.7</td>
<td align="left" rowspan="1" colspan="1">29.9</td>
<td align="left" rowspan="1" colspan="1">52</td>
<td align="left" rowspan="1" colspan="1">0</td>
<td align="left" rowspan="1" colspan="1">N/A</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1"><bold>Cohn E.W. et al./2008/II</bold></td>
<td align="left" rowspan="1" colspan="1">Thyroid cancer</td>
<td align="left" rowspan="1" colspan="1">60</td>
<td align="left" rowspan="1" colspan="1">Axitinib 5 mg bid po</td>
<td align="left" rowspan="1" colspan="1">59</td>
<td align="left" rowspan="1" colspan="1">4.8</td>
<td align="left" rowspan="1" colspan="1">18.1</td>
<td align="left" rowspan="1" colspan="1">NR</td>
<td align="left" rowspan="1" colspan="1">60</td>
<td align="left" rowspan="1" colspan="1">3</td>
<td align="left" rowspan="1" colspan="1">N/A</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1"><bold>Spano J.P. et al./2009/II</bold></td>
<td align="left" rowspan="1" colspan="1">Pancreatic cancer</td>
<td align="left" rowspan="1" colspan="1">103</td>
<td align="left" rowspan="1" colspan="1">Axitinib 5 mg bid po+GEM</td>
<td align="left" rowspan="1" colspan="1">65.0</td>
<td align="left" rowspan="1" colspan="1">3.8</td>
<td align="left" rowspan="1" colspan="1">4.2</td>
<td align="left" rowspan="1" colspan="1">6.9</td>
<td align="left" rowspan="1" colspan="1">68</td>
<td align="left" rowspan="1" colspan="1">0</td>
<td align="left" rowspan="1" colspan="1">3</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1">GEM</td>
<td align="left" rowspan="1" colspan="1">61.0</td>
<td align="left" rowspan="1" colspan="1">NR</td>
<td align="left" rowspan="1" colspan="1">3.7</td>
<td align="left" rowspan="1" colspan="1">5.6</td>
<td align="left" rowspan="1" colspan="1">31</td>
<td align="left" rowspan="1" colspan="1">0</td>
<td align="left" rowspan="1" colspan="1"/>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1"><bold>Sleijfer S. et al/2009/II</bold></td>
<td align="left" rowspan="1" colspan="1">STS</td>
<td align="left" rowspan="1" colspan="1">142</td>
<td align="left" rowspan="1" colspan="1">Pazopanib 800 mg qd po.</td>
<td align="left" rowspan="1" colspan="1">NR</td>
<td align="left" rowspan="1" colspan="1">NR</td>
<td align="left" rowspan="1" colspan="1">NR</td>
<td align="left" rowspan="1" colspan="1">NR</td>
<td align="left" rowspan="1" colspan="1">142</td>
<td align="left" rowspan="1" colspan="1">0</td>
<td align="left" rowspan="1" colspan="1">N/A</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1"><bold>Batchelor T.T. et al/2010/II</bold></td>
<td align="left" rowspan="1" colspan="1">Glioblastoma</td>
<td align="left" rowspan="1" colspan="1">31</td>
<td align="left" rowspan="1" colspan="1">Cediranib 45 mg/d</td>
<td align="left" rowspan="1" colspan="1">53</td>
<td align="left" rowspan="1" colspan="1">NR</td>
<td align="left" rowspan="1" colspan="1">3.9</td>
<td align="left" rowspan="1" colspan="1">7.6</td>
<td align="left" rowspan="1" colspan="1">31</td>
<td align="left" rowspan="1" colspan="1">1</td>
<td align="left" rowspan="1" colspan="1">N/A</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1"><bold>Bible K.C. et al/2010/II</bold></td>
<td align="left" rowspan="1" colspan="1">Thyroid cancer</td>
<td align="left" rowspan="1" colspan="1">39</td>
<td align="left" rowspan="1" colspan="1">Pazopanib 800 mg</td>
<td align="left" rowspan="1" colspan="1">63</td>
<td align="left" rowspan="1" colspan="1">11.2</td>
<td align="left" rowspan="1" colspan="1">NR</td>
<td align="left" rowspan="1" colspan="1">NR</td>
<td align="left" rowspan="1" colspan="1">39</td>
<td align="left" rowspan="1" colspan="1">0</td>
<td align="left" rowspan="1" colspan="1">N/A</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1"><bold>Hsu C.H, et al./2010/II</bold></td>
<td align="left" rowspan="1" colspan="1">Hepatocellular carcinoma</td>
<td align="left" rowspan="1" colspan="1">53</td>
<td align="left" rowspan="1" colspan="1">Sorafenib 400 mg bid po</td>
<td align="left" rowspan="1" colspan="1">57</td>
<td align="left" rowspan="1" colspan="1">3.7</td>
<td align="left" rowspan="1" colspan="1">3.7</td>
<td align="left" rowspan="1" colspan="1">7.4</td>
<td align="left" rowspan="1" colspan="1">53</td>
<td align="left" rowspan="1" colspan="1">0</td>
<td align="left" rowspan="1" colspan="1">N/A</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1"><bold>Iwamoto F.M. et al/2010/II</bold></td>
<td align="left" rowspan="1" colspan="1">Glioblastoma</td>
<td align="left" rowspan="1" colspan="1">35</td>
<td align="left" rowspan="1" colspan="1">Pazopanib 800 mg</td>
<td align="left" rowspan="1" colspan="1">53</td>
<td align="left" rowspan="1" colspan="1">NR</td>
<td align="left" rowspan="1" colspan="1">NR</td>
<td align="left" rowspan="1" colspan="1">NR</td>
<td align="left" rowspan="1" colspan="1">35</td>
<td align="left" rowspan="1" colspan="1">NR</td>
<td align="left" rowspan="1" colspan="1">N/A</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1"><bold>Jonasch E. et al/2010/II</bold></td>
<td align="left" rowspan="1" colspan="1">RCC</td>
<td align="left" rowspan="1" colspan="1">80</td>
<td align="left" rowspan="1" colspan="1">Sorafenib 400 mg bid</td>
<td align="left" rowspan="1" colspan="1">62.4</td>
<td align="left" rowspan="1" colspan="1">NR</td>
<td align="left" rowspan="1" colspan="1">7.39</td>
<td align="left" rowspan="1" colspan="1">NR</td>
<td align="left" rowspan="1" colspan="1">40</td>
<td align="left" rowspan="1" colspan="1">1</td>
<td align="left" rowspan="1" colspan="1">2</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1">Sorafenib 400 mg+IFN</td>
<td align="left" rowspan="1" colspan="1">60.7</td>
<td align="left" rowspan="1" colspan="1">NR</td>
<td align="left" rowspan="1" colspan="1">7.56</td>
<td align="left" rowspan="1" colspan="1">27.04</td>
<td align="left" rowspan="1" colspan="1">40</td>
<td align="left" rowspan="1" colspan="1">2</td>
<td align="left" rowspan="1" colspan="1"/>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1"><bold>Mayer E.L. et al/2010/II</bold></td>
<td align="left" rowspan="1" colspan="1">Breast cancer</td>
<td align="left" rowspan="1" colspan="1">46</td>
<td align="left" rowspan="1" colspan="1">PTX+Bev+Sunitinib</td>
<td align="left" rowspan="1" colspan="1">58</td>
<td align="left" rowspan="1" colspan="1">2.6</td>
<td align="left" rowspan="1" colspan="1">NR</td>
<td align="left" rowspan="1" colspan="1">NR</td>
<td align="left" rowspan="1" colspan="1">23</td>
<td align="left" rowspan="1" colspan="1">0</td>
<td align="left" rowspan="1" colspan="1">2</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1">PTX+Bev</td>
<td align="left" rowspan="1" colspan="1">52</td>
<td align="left" rowspan="1" colspan="1">3.3</td>
<td align="left" rowspan="1" colspan="1">NR</td>
<td align="left" rowspan="1" colspan="1">NR</td>
<td align="left" rowspan="1" colspan="1">23</td>
<td align="left" rowspan="1" colspan="1">0</td>
<td align="left" rowspan="1" colspan="1"/>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1"><bold>Ramalingam S.S. et al./2010/II</bold></td>
<td align="left" rowspan="1" colspan="1">SCLC</td>
<td align="left" rowspan="1" colspan="1">25</td>
<td align="left" rowspan="1" colspan="1">Cediranib 45 mg or 30 mg po</td>
<td align="left" rowspan="1" colspan="1">61</td>
<td align="left" rowspan="1" colspan="1">NR</td>
<td align="left" rowspan="1" colspan="1">2</td>
<td align="left" rowspan="1" colspan="1">6</td>
<td align="left" rowspan="1" colspan="1">25</td>
<td align="left" rowspan="1" colspan="1">3</td>
<td align="left" rowspan="1" colspan="1">N/A</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1"><bold>Robinson E.S. et al./2010/II</bold></td>
<td align="left" rowspan="1" colspan="1">Ovarian cancer</td>
<td align="left" rowspan="1" colspan="1">31</td>
<td align="left" rowspan="1" colspan="1">Cediranib 45 mg po</td>
<td align="left" rowspan="1" colspan="1">57</td>
<td align="left" rowspan="1" colspan="1">2.8</td>
<td align="left" rowspan="1" colspan="1">NR</td>
<td align="left" rowspan="1" colspan="1">NR</td>
<td align="left" rowspan="1" colspan="1">31</td>
<td align="left" rowspan="1" colspan="1">0</td>
<td align="left" rowspan="1" colspan="1">N/A</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1"><bold>Lim W.T. et al/2011/II</bold></td>
<td align="left" rowspan="1" colspan="1">Nasopharyngeal carcinoma</td>
<td align="left" rowspan="1" colspan="1">33</td>
<td align="left" rowspan="1" colspan="1">Pazopanib 800 mg</td>
<td align="left" rowspan="1" colspan="1">50</td>
<td align="left" rowspan="1" colspan="1">NR</td>
<td align="left" rowspan="1" colspan="1">4.4</td>
<td align="left" rowspan="1" colspan="1">10.8</td>
<td align="left" rowspan="1" colspan="1">33</td>
<td align="left" rowspan="1" colspan="1">1</td>
<td align="left" rowspan="1" colspan="1">N/A</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1"><bold>Tan E.H. et al./2011/II</bold></td>
<td align="left" rowspan="1" colspan="1">NSCLC</td>
<td align="left" rowspan="1" colspan="1">139</td>
<td align="left" rowspan="1" colspan="1">Linifanib 0.1 mg/kg or 0.25 mg/kg po</td>
<td align="left" rowspan="1" colspan="1">62</td>
<td align="left" rowspan="1" colspan="1">NR</td>
<td align="left" rowspan="1" colspan="1">3.0</td>
<td align="left" rowspan="1" colspan="1">9.0</td>
<td align="left" rowspan="1" colspan="1">139</td>
<td align="left" rowspan="1" colspan="1">11</td>
<td align="left" rowspan="1" colspan="1">N/A</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1"><bold>Tannir N.M. et al./2011/II</bold></td>
<td align="left" rowspan="1" colspan="1">RCC</td>
<td align="left" rowspan="1" colspan="1">53</td>
<td align="left" rowspan="1" colspan="1">Linifanib 0.25 mg/kg po</td>
<td align="left" rowspan="1" colspan="1">61</td>
<td align="left" rowspan="1" colspan="1">NR</td>
<td align="left" rowspan="1" colspan="1">5.4</td>
<td align="left" rowspan="1" colspan="1">14.5</td>
<td align="left" rowspan="1" colspan="1">53</td>
<td align="left" rowspan="1" colspan="1">3</td>
<td align="left" rowspan="1" colspan="1">N/A</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1"><bold>Tomita Y. et al/2011/II</bold></td>
<td align="left" rowspan="1" colspan="1">RCC</td>
<td align="left" rowspan="1" colspan="1">64</td>
<td align="left" rowspan="1" colspan="1">Axitinib 5 mg bid po</td>
<td align="left" rowspan="1" colspan="1">63</td>
<td align="left" rowspan="1" colspan="1">10.9</td>
<td align="left" rowspan="1" colspan="1">11.0</td>
<td align="left" rowspan="1" colspan="1">NR</td>
<td align="left" rowspan="1" colspan="1">64</td>
<td align="left" rowspan="1" colspan="1">6</td>
<td align="left" rowspan="1" colspan="1">N/A</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1"><bold>Campbell N.P. et al./2011/II</bold></td>
<td align="left" rowspan="1" colspan="1">Malignant mesothelioma</td>
<td align="left" rowspan="1" colspan="1">51</td>
<td align="left" rowspan="1" colspan="1">Cediranib 45 mg or 30 mg qd po</td>
<td align="left" rowspan="1" colspan="1">NR</td>
<td align="left" rowspan="1" colspan="1">NR</td>
<td align="left" rowspan="1" colspan="1">1.8</td>
<td align="left" rowspan="1" colspan="1">4.4</td>
<td align="left" rowspan="1" colspan="1">51</td>
<td align="left" rowspan="1" colspan="1">NR</td>
<td align="left" rowspan="1" colspan="1">N/A</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1"><bold>Kindler H.L. et al/2012/II</bold></td>
<td align="left" rowspan="1" colspan="1">Pancreatic cancer</td>
<td align="left" rowspan="1" colspan="1">17</td>
<td align="left" rowspan="1" colspan="1">Sorafenib 400 mg bid po+GEM</td>
<td align="left" rowspan="1" colspan="1">62</td>
<td align="left" rowspan="1" colspan="1">NR</td>
<td align="left" rowspan="1" colspan="1">3.2</td>
<td align="left" rowspan="1" colspan="1">4.0</td>
<td align="left" rowspan="1" colspan="1">17</td>
<td align="left" rowspan="1" colspan="1">0</td>
<td align="left" rowspan="1" colspan="1">N/A</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1"><bold>Mulders P. et al/2011/II</bold></td>
<td align="left" rowspan="1" colspan="1">RCC</td>
<td align="left" rowspan="1" colspan="1">71</td>
<td align="left" rowspan="1" colspan="1">Cediranib 45 mg</td>
<td align="left" rowspan="1" colspan="1">60</td>
<td align="left" rowspan="1" colspan="1">NR</td>
<td align="left" rowspan="1" colspan="1">12.1</td>
<td align="left" rowspan="1" colspan="1">NR</td>
<td align="left" rowspan="1" colspan="1">53</td>
<td align="left" rowspan="1" colspan="1">0</td>
<td align="left" rowspan="1" colspan="1">5</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1">Placebo</td>
<td align="left" rowspan="1" colspan="1">61</td>
<td align="left" rowspan="1" colspan="1">NR</td>
<td align="left" rowspan="1" colspan="1">2.8</td>
<td align="left" rowspan="1" colspan="1">NR</td>
<td align="left" rowspan="1" colspan="1">18</td>
<td align="left" rowspan="1" colspan="1">0</td>
<td align="left" rowspan="1" colspan="1"/>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1"><bold>Nosov D.A. et al/2012/II</bold></td>
<td align="left" rowspan="1" colspan="1">RCC</td>
<td align="left" rowspan="1" colspan="1">272</td>
<td align="left" rowspan="1" colspan="1">Tivozanib 1.5 mg qd po.</td>
<td align="left" rowspan="1" colspan="1">56</td>
<td align="left" rowspan="1" colspan="1">NR</td>
<td align="left" rowspan="1" colspan="1">NR</td>
<td align="left" rowspan="1" colspan="1">NR</td>
<td align="left" rowspan="1" colspan="1">272</td>
<td align="left" rowspan="1" colspan="1">5</td>
<td align="left" rowspan="1" colspan="1">N/A</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1"><bold>Rini B. et al/2012/II</bold></td>
<td align="left" rowspan="1" colspan="1">RCC</td>
<td align="left" rowspan="1" colspan="1">152</td>
<td align="left" rowspan="1" colspan="1">Sorafenib+AMG-386 10 mg/kg</td>
<td align="left" rowspan="1" colspan="1">60</td>
<td align="left" rowspan="1" colspan="1">NR</td>
<td align="left" rowspan="1" colspan="1">9.0</td>
<td align="left" rowspan="1" colspan="1">NR</td>
<td align="left" rowspan="1" colspan="1">50</td>
<td align="left" rowspan="1" colspan="1">2</td>
<td align="left" rowspan="1" colspan="1">4</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1">Sorafenib+AMG-386 3 mg/kg</td>
<td align="left" rowspan="1" colspan="1">58</td>
<td align="left" rowspan="1" colspan="1">NR</td>
<td align="left" rowspan="1" colspan="1">8.5</td>
<td align="left" rowspan="1" colspan="1">NR</td>
<td align="left" rowspan="1" colspan="1">51</td>
<td align="left" rowspan="1" colspan="1">0</td>
<td align="left" rowspan="1" colspan="1"/>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1">Sorafenib+placebo</td>
<td align="left" rowspan="1" colspan="1">59</td>
<td align="left" rowspan="1" colspan="1">NR</td>
<td align="left" rowspan="1" colspan="1">9.0</td>
<td align="left" rowspan="1" colspan="1">NR</td>
<td align="left" rowspan="1" colspan="1">50</td>
<td align="left" rowspan="1" colspan="1">0</td>
<td align="left" rowspan="1" colspan="1"/>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1"><bold>Schmoll H.J. et al/2012/III</bold></td>
<td align="left" rowspan="1" colspan="1">CRC</td>
<td align="left" rowspan="1" colspan="1">1422</td>
<td align="left" rowspan="1" colspan="1">Cediranib 20 mg+mFOLFOX6</td>
<td align="left" rowspan="1" colspan="1">59</td>
<td align="left" rowspan="1" colspan="1">6.7</td>
<td align="left" rowspan="1" colspan="1">9.9</td>
<td align="left" rowspan="1" colspan="1">22.8</td>
<td align="left" rowspan="1" colspan="1">705</td>
<td align="left" rowspan="1" colspan="1">7</td>
<td align="left" rowspan="1" colspan="1">3</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1">Bevacizumab+mFOLFOX6</td>
<td align="left" rowspan="1" colspan="1">60</td>
<td align="left" rowspan="1" colspan="1">7.0</td>
<td align="left" rowspan="1" colspan="1">10.3</td>
<td align="left" rowspan="1" colspan="1">21.3</td>
<td align="left" rowspan="1" colspan="1">704</td>
<td align="left" rowspan="1" colspan="1">6</td>
<td align="left" rowspan="1" colspan="1"/>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1"><bold>Wells S.A. et al/2012/III</bold></td>
<td align="left" rowspan="1" colspan="1">Thyroid cancer</td>
<td align="left" rowspan="1" colspan="1">331</td>
<td align="left" rowspan="1" colspan="1">Vandetanib 300 mg</td>
<td align="left" rowspan="1" colspan="1">50.7</td>
<td align="left" rowspan="1" colspan="1">21.0</td>
<td align="left" rowspan="1" colspan="1">NR</td>
<td align="left" rowspan="1" colspan="1">NR</td>
<td align="left" rowspan="1" colspan="1">231</td>
<td align="left" rowspan="1" colspan="1">0</td>
<td align="left" rowspan="1" colspan="1">5</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1">Placebo</td>
<td align="left" rowspan="1" colspan="1">53.4</td>
<td align="left" rowspan="1" colspan="1">9.3</td>
<td align="left" rowspan="1" colspan="1">19.3</td>
<td align="left" rowspan="1" colspan="1">NR</td>
<td align="left" rowspan="1" colspan="1">99</td>
<td align="left" rowspan="1" colspan="1">0</td>
<td align="left" rowspan="1" colspan="1"/>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1"><bold>Motzer R. et al/2012/III</bold></td>
<td align="left" rowspan="1" colspan="1">RCC</td>
<td align="left" rowspan="1" colspan="1">517</td>
<td align="left" rowspan="1" colspan="1">Tivozanib 1.5 mg/d</td>
<td align="left" rowspan="1" colspan="1">59</td>
<td align="left" rowspan="1" colspan="1">NR</td>
<td align="left" rowspan="1" colspan="1">11.9</td>
<td align="left" rowspan="1" colspan="1">NR</td>
<td align="left" rowspan="1" colspan="1">259</td>
<td align="left" rowspan="1" colspan="1">3</td>
<td align="left" rowspan="1" colspan="1">3</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1">Sorafenib 400 mg</td>
<td align="left" rowspan="1" colspan="1">59</td>
<td align="left" rowspan="1" colspan="1">NR</td>
<td align="left" rowspan="1" colspan="1">9.1</td>
<td align="left" rowspan="1" colspan="1">NR</td>
<td align="left" rowspan="1" colspan="1">257</td>
<td align="left" rowspan="1" colspan="1">2</td>
<td align="left" rowspan="1" colspan="1"/>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1"><bold>Van der Graaf W.T. et al./2012/III</bold></td>
<td align="left" rowspan="1" colspan="1">STS</td>
<td align="left" rowspan="1" colspan="1">372</td>
<td align="left" rowspan="1" colspan="1">Pazopanib 800 mg</td>
<td align="left" rowspan="1" colspan="1">51.9</td>
<td align="left" rowspan="1" colspan="1">3.8</td>
<td align="left" rowspan="1" colspan="1">4.6</td>
<td align="left" rowspan="1" colspan="1">11.9</td>
<td align="left" rowspan="1" colspan="1">239</td>
<td align="left" rowspan="1" colspan="1">1</td>
<td align="left" rowspan="1" colspan="1">5</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1">Placebo</td>
<td align="left" rowspan="1" colspan="1">56.7</td>
<td align="left" rowspan="1" colspan="1">1.9</td>
<td align="left" rowspan="1" colspan="1">1.6</td>
<td align="left" rowspan="1" colspan="1">10.4</td>
<td align="left" rowspan="1" colspan="1">123</td>
<td align="left" rowspan="1" colspan="1">0</td>
<td align="left" rowspan="1" colspan="1"/>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1"><bold>Cunningham D. et al/2013/II</bold></td>
<td align="left" rowspan="1" colspan="1">CRC</td>
<td align="left" rowspan="1" colspan="1">210</td>
<td align="left" rowspan="1" colspan="1">Cediranib 30 mg+FOLFOX</td>
<td align="left" rowspan="1" colspan="1">NR</td>
<td align="left" rowspan="1" colspan="1">5.0</td>
<td align="left" rowspan="1" colspan="1">5.8</td>
<td align="left" rowspan="1" colspan="1">14.3</td>
<td align="left" rowspan="1" colspan="1">70</td>
<td align="left" rowspan="1" colspan="1">0</td>
<td align="left" rowspan="1" colspan="1">3</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1">Cediranib 20 mg+FOLFOX</td>
<td align="left" rowspan="1" colspan="1">NR</td>
<td align="left" rowspan="1" colspan="1">5.4</td>
<td align="left" rowspan="1" colspan="1">7.2</td>
<td align="left" rowspan="1" colspan="1">16.8</td>
<td align="left" rowspan="1" colspan="1">73</td>
<td align="left" rowspan="1" colspan="1">6</td>
<td align="left" rowspan="1" colspan="1"/>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1">Bev+FOLFOX</td>
<td align="left" rowspan="1" colspan="1">NR</td>
<td align="left" rowspan="1" colspan="1">6.3</td>
<td align="left" rowspan="1" colspan="1">7.8</td>
<td align="left" rowspan="1" colspan="1">19.6</td>
<td align="left" rowspan="1" colspan="1">66</td>
<td align="left" rowspan="1" colspan="1">2</td>
<td align="left" rowspan="1" colspan="1"/>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1"><bold>Grothey A. et al/2013/III</bold></td>
<td align="left" rowspan="1" colspan="1">CRC</td>
<td align="left" rowspan="1" colspan="1">1052</td>
<td align="left" rowspan="1" colspan="1">Regorafenib 160 mg</td>
<td align="left" rowspan="1" colspan="1">61</td>
<td align="left" rowspan="1" colspan="1">2.8</td>
<td align="left" rowspan="1" colspan="1">NR</td>
<td align="left" rowspan="1" colspan="1">6.4</td>
<td align="left" rowspan="1" colspan="1">500</td>
<td align="left" rowspan="1" colspan="1">7</td>
<td align="left" rowspan="1" colspan="1">5</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1">Placebo</td>
<td align="left" rowspan="1" colspan="1">61</td>
<td align="left" rowspan="1" colspan="1">1.8</td>
<td align="left" rowspan="1" colspan="1">NR</td>
<td align="left" rowspan="1" colspan="1">5.0</td>
<td align="left" rowspan="1" colspan="1">253</td>
<td align="left" rowspan="1" colspan="1">1</td>
<td align="left" rowspan="1" colspan="1"/>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1"><bold>Hainsworth J.D. et al/2013/II</bold></td>
<td align="left" rowspan="1" colspan="1">RCC</td>
<td align="left" rowspan="1" colspan="1">55</td>
<td align="left" rowspan="1" colspan="1">Pazopanib 800 mg qd po</td>
<td align="left" rowspan="1" colspan="1">60</td>
<td align="left" rowspan="1" colspan="1">6</td>
<td align="left" rowspan="1" colspan="1">7.5</td>
<td align="left" rowspan="1" colspan="1">NR</td>
<td align="left" rowspan="1" colspan="1">55</td>
<td align="left" rowspan="1" colspan="1">7</td>
<td align="left" rowspan="1" colspan="1">N/A</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1"><bold>Infante J.R. et al./2013/II</bold></td>
<td align="left" rowspan="1" colspan="1">CRC</td>
<td align="left" rowspan="1" colspan="1">126</td>
<td align="left" rowspan="1" colspan="1">Axitinib 5 mg bid+FOLFOX</td>
<td align="left" rowspan="1" colspan="1">61</td>
<td align="left" rowspan="1" colspan="1">NR</td>
<td align="left" rowspan="1" colspan="1">11.0</td>
<td align="left" rowspan="1" colspan="1">18.1</td>
<td align="left" rowspan="1" colspan="1">42</td>
<td align="left" rowspan="1" colspan="1">1</td>
<td align="left" rowspan="1" colspan="1">3</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1">Bevacizumab+FOLFOX</td>
<td align="left" rowspan="1" colspan="1">64</td>
<td align="left" rowspan="1" colspan="1">NR</td>
<td align="left" rowspan="1" colspan="1">15.9</td>
<td align="left" rowspan="1" colspan="1">21.6</td>
<td align="left" rowspan="1" colspan="1">43</td>
<td align="left" rowspan="1" colspan="1">0</td>
<td align="left" rowspan="1" colspan="1"/>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1">Axitinib+bevacizumab+FOLFOX</td>
<td align="left" rowspan="1" colspan="1">59</td>
<td align="left" rowspan="1" colspan="1">NR</td>
<td align="left" rowspan="1" colspan="1">12.5</td>
<td align="left" rowspan="1" colspan="1">19.7</td>
<td align="left" rowspan="1" colspan="1">41</td>
<td align="left" rowspan="1" colspan="1">2</td>
<td align="left" rowspan="1" colspan="1"/>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1"><bold>Kummar S. et al/2013/II</bold></td>
<td align="left" rowspan="1" colspan="1">Alveolar soft part sarcoma</td>
<td align="left" rowspan="1" colspan="1">46</td>
<td align="left" rowspan="1" colspan="1">Cediranib 30 mg</td>
<td align="left" rowspan="1" colspan="1">27</td>
<td align="left" rowspan="1" colspan="1">NR</td>
<td align="left" rowspan="1" colspan="1">NR</td>
<td align="left" rowspan="1" colspan="1">NR</td>
<td align="left" rowspan="1" colspan="1">46</td>
<td align="left" rowspan="1" colspan="1">1</td>
<td align="left" rowspan="1" colspan="1">N/A</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1"><bold>Motzer R. et al/2013/III</bold></td>
<td align="left" rowspan="1" colspan="1">RCC</td>
<td align="left" rowspan="1" colspan="1">723</td>
<td align="left" rowspan="1" colspan="1">Axitinib 5 mg bid po</td>
<td align="left" rowspan="1" colspan="1">61</td>
<td align="left" rowspan="1" colspan="1">6.4</td>
<td align="left" rowspan="1" colspan="1">8.3</td>
<td align="left" rowspan="1" colspan="1">20.1</td>
<td align="left" rowspan="1" colspan="1">359</td>
<td align="left" rowspan="1" colspan="1">11</td>
<td align="left" rowspan="1" colspan="1">3</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1">Sorafenib 400 mg bid po</td>
<td align="left" rowspan="1" colspan="1">61</td>
<td align="left" rowspan="1" colspan="1">5.0</td>
<td align="left" rowspan="1" colspan="1">5.7</td>
<td align="left" rowspan="1" colspan="1">19.2</td>
<td align="left" rowspan="1" colspan="1">355</td>
<td align="left" rowspan="1" colspan="1">4</td>
<td align="left" rowspan="1" colspan="1"/>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1"><bold>Sternberg C.N. et al/2013/III</bold></td>
<td align="left" rowspan="1" colspan="1">RCC</td>
<td align="left" rowspan="1" colspan="1">435</td>
<td align="left" rowspan="1" colspan="1">Pazopanib 800 mg po qd</td>
<td align="left" rowspan="1" colspan="1">59</td>
<td align="left" rowspan="1" colspan="1">7.4</td>
<td align="left" rowspan="1" colspan="1">9.2</td>
<td align="left" rowspan="1" colspan="1">22.9</td>
<td align="left" rowspan="1" colspan="1">290</td>
<td align="left" rowspan="1" colspan="1">7</td>
<td align="left" rowspan="1" colspan="1">5</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1">Placebo</td>
<td align="left" rowspan="1" colspan="1">60</td>
<td align="left" rowspan="1" colspan="1">3.8</td>
<td align="left" rowspan="1" colspan="1">4.2</td>
<td align="left" rowspan="1" colspan="1">20.5</td>
<td align="left" rowspan="1" colspan="1">145</td>
<td align="left" rowspan="1" colspan="1">0</td>
<td align="left" rowspan="1" colspan="1"/>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1"><bold>Toh H.C. et al/2013/II</bold></td>
<td align="left" rowspan="1" colspan="1">Hepatocellular carcinoma</td>
<td align="left" rowspan="1" colspan="1">44</td>
<td align="left" rowspan="1" colspan="1">Linifanib 0.25 mg/kg po</td>
<td align="left" rowspan="1" colspan="1">62.5</td>
<td align="left" rowspan="1" colspan="1">NR</td>
<td align="left" rowspan="1" colspan="1">3.7</td>
<td align="left" rowspan="1" colspan="1">9.7</td>
<td align="left" rowspan="1" colspan="1">44</td>
<td align="left" rowspan="1" colspan="1">0</td>
<td align="left" rowspan="1" colspan="1">N/A</td>
</tr>
</tbody>
</table>
</alternatives><table-wrap-foot><fn id="nt101"><label/><p>Abbreviations: PFS, progression-free survival; OS, overall survival; RCC, renal cell cancer; NSCLC, non-small-cell lung carcinoma; SCLC, small-cell lung cancer; CRC, Colorectal cancer; STS, soft tissue sarcoma; Bev, bevacizumab; GEM, gemcitabine; PTX, paclitaxel; NR, not reported; N/A, not applicable.</p></fn></table-wrap-foot></table-wrap></sec><sec id="s3b">
<title>Incidence of all-grade proteinuria events</title>
<p>A total of 3,<italic>701</italic> patients receiving VEGFR-TKIs single agents in 23 trials were available for analysis. In two phase III trials, patients in both groups received VEGFR-TKIs single agent, thus both arms were included in this analysis <xref ref-type="bibr" rid="pone.0090135-Motzer2">[53]</xref>, <xref ref-type="bibr" rid="pone.0090135-Motzer3">[58]</xref>. There were <italic>604</italic> total proteinuria events among these patients. The highest incidence (57.8%; 95% CI, 45.2%–69.2%) as observed in a phase II trial of renal cell cancer patients treated with axitinib <xref ref-type="bibr" rid="pone.0090135-Tomita1">[39]</xref>, and the lowest incidence was observed in a phase III trials of soft tissue sarcoma patients treated with pazopanib in which two proteinuria event occurred <xref ref-type="bibr" rid="pone.0090135-vanderGraaf1">[66]</xref>. Using a random-effects model (χ<sup>2</sup>-based Q statistic test: Q = 400.96; <italic>P</italic>&lt;<italic>0.001</italic>; <italic>I</italic><sup>2</sup> = 94%), the summary incidence of all-grade proteinuria events in patients receiving VEGFR-TKIs was 18.7% (95% CI, 13.3%–25.6%, <xref ref-type="table" rid="pone-0090135-t003">table 3</xref>).</p>
<table-wrap id="pone-0090135-t003" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0090135.t003</object-id><label>Table 3</label><caption>
<title>Incidence for proteinuria with VEGFR-TKIs according to drugs and tumor types.</title>
</caption><alternatives><graphic id="pone-0090135-t003-3" position="float" mimetype="image" xlink:href="info:doi/10.1371/journal.pone.0090135.t003" xlink:type="simple"/>
<table><colgroup span="1"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/></colgroup>
<thead>
<tr>
<td align="left" rowspan="1" colspan="1">Grade</td>
<td align="left" rowspan="1" colspan="1">Categories</td>
<td align="left" rowspan="1" colspan="1">No. of studies</td>
<td align="left" rowspan="1" colspan="1">Proteinuria events</td>
<td align="left" rowspan="1" colspan="1">Sample size</td>
<td align="left" rowspan="1" colspan="1">Incidence (%;95%CI)</td>
<td align="left" rowspan="1" colspan="1">Relative risk (95%CI)</td>
<td align="left" rowspan="1" colspan="1"><italic>P</italic> values</td>
</tr>
</thead>
<tbody>
<tr>
<td align="left" rowspan="1" colspan="1"><bold>All-grade</bold></td>
<td align="left" rowspan="1" colspan="1">Overall</td>
<td align="left" rowspan="1" colspan="1">23</td>
<td align="left" rowspan="1" colspan="1">604</td>
<td align="left" rowspan="1" colspan="1">3701</td>
<td align="left" rowspan="1" colspan="1">18.7% (13.3–25.6%)</td>
<td align="left" rowspan="1" colspan="1">NA</td>
<td align="left" rowspan="1" colspan="1">NA</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1">Non-RCC</td>
<td align="left" rowspan="1" colspan="1">14</td>
<td align="left" rowspan="1" colspan="1">261</td>
<td align="left" rowspan="1" colspan="1">1635</td>
<td align="left" rowspan="1" colspan="1">18.5% (10.7–29.9%)</td>
<td align="left" rowspan="1" colspan="1">1</td>
<td align="left" rowspan="1" colspan="1">NA</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1">RCC</td>
<td align="left" rowspan="1" colspan="1">9</td>
<td align="left" rowspan="1" colspan="1">343</td>
<td align="left" rowspan="1" colspan="1">2066</td>
<td align="left" rowspan="1" colspan="1">18.4% (11.5–28.3%)</td>
<td align="left" rowspan="1" colspan="1">1.05(0.88–1.25)</td>
<td align="left" rowspan="1" colspan="1">0.60</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1">Sorafenib</td>
<td align="left" rowspan="1" colspan="1">4</td>
<td align="left" rowspan="1" colspan="1">108</td>
<td align="left" rowspan="1" colspan="1">715</td>
<td align="left" rowspan="1" colspan="1">11.6% (4.3–27.6%)</td>
<td align="left" rowspan="1" colspan="1">1</td>
<td align="left" rowspan="1" colspan="1">NA</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1">Axitinib</td>
<td align="left" rowspan="1" colspan="1">4</td>
<td align="left" rowspan="1" colspan="1">97</td>
<td align="left" rowspan="1" colspan="1">535</td>
<td align="left" rowspan="1" colspan="1">20.2% (6.9–46.7%)</td>
<td align="left" rowspan="1" colspan="1">1.24 (0.92–1.68)</td>
<td align="left" rowspan="1" colspan="1">0.15</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1">Pazopanib</td>
<td align="left" rowspan="1" colspan="1">5</td>
<td align="left" rowspan="1" colspan="1">131</td>
<td align="left" rowspan="1" colspan="1">761</td>
<td align="left" rowspan="1" colspan="1">13.5% (3.9–37.6%)</td>
<td align="left" rowspan="1" colspan="1">1.17 (0.88–1.54)</td>
<td align="left" rowspan="1" colspan="1">0.27</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1">Vandetanib</td>
<td align="left" rowspan="1" colspan="1">1</td>
<td align="left" rowspan="1" colspan="1">23</td>
<td align="left" rowspan="1" colspan="1">231</td>
<td align="left" rowspan="1" colspan="1">10.0% (6.7–14.5%)</td>
<td align="left" rowspan="1" colspan="1">0.62 (0.39–1.00)</td>
<td align="left" rowspan="1" colspan="1">0.05</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1">Regorafenib</td>
<td align="left" rowspan="1" colspan="1">1</td>
<td align="left" rowspan="1" colspan="1">35</td>
<td align="left" rowspan="1" colspan="1">500</td>
<td align="left" rowspan="1" colspan="1">7.0% (5.1–9.6%)</td>
<td align="left" rowspan="1" colspan="1">0.42 (0.28–0.63)</td>
<td align="left" rowspan="1" colspan="1">0.001</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1">Cediranib</td>
<td align="left" rowspan="1" colspan="1">5</td>
<td align="left" rowspan="1" colspan="1">73</td>
<td align="left" rowspan="1" colspan="1">192</td>
<td align="left" rowspan="1" colspan="1">37.8% (27.5–49.3%)</td>
<td align="left" rowspan="1" colspan="1">3.45 (2.41–4.92)</td>
<td align="left" rowspan="1" colspan="1">0.001</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1">Tivozanib</td>
<td align="left" rowspan="1" colspan="1">2</td>
<td align="left" rowspan="1" colspan="1">76</td>
<td align="left" rowspan="1" colspan="1">531</td>
<td align="left" rowspan="1" colspan="1">9.6% (0.9–54.3%)</td>
<td align="left" rowspan="1" colspan="1">0.94 (0.68–1.29)</td>
<td align="left" rowspan="1" colspan="1">0.70</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1">Linifanib</td>
<td align="left" rowspan="1" colspan="1">3</td>
<td align="left" rowspan="1" colspan="1">61</td>
<td align="left" rowspan="1" colspan="1">236</td>
<td align="left" rowspan="1" colspan="1">27.3% (18.6–38.1%)</td>
<td align="left" rowspan="1" colspan="1">1.96 (1.37–2.80)</td>
<td align="left" rowspan="1" colspan="1">0.002</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1"><bold>High-grade</bold></td>
<td align="left" rowspan="1" colspan="1">Overall</td>
<td align="left" rowspan="1" colspan="1">25</td>
<td align="left" rowspan="1" colspan="1">76</td>
<td align="left" rowspan="1" colspan="1">3812</td>
<td align="left" rowspan="1" colspan="1">2.4% (1.6–3.7%)</td>
<td align="left" rowspan="1" colspan="1">NA</td>
<td align="left" rowspan="1" colspan="1">NA</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1">Non-RCC</td>
<td align="left" rowspan="1" colspan="1">14</td>
<td align="left" rowspan="1" colspan="1">28</td>
<td align="left" rowspan="1" colspan="1">1613</td>
<td align="left" rowspan="1" colspan="1">2.3% (1.2–4.4%)</td>
<td align="left" rowspan="1" colspan="1">1</td>
<td align="left" rowspan="1" colspan="1">NA</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1">RCC</td>
<td align="left" rowspan="1" colspan="1">11</td>
<td align="left" rowspan="1" colspan="1">48</td>
<td align="left" rowspan="1" colspan="1">2199</td>
<td align="left" rowspan="1" colspan="1">2.5% (1.4–4.4%)</td>
<td align="left" rowspan="1" colspan="1">1.26 (0.79–2.02)</td>
<td align="left" rowspan="1" colspan="1">0.33</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1">Sorafenib</td>
<td align="left" rowspan="1" colspan="1">5</td>
<td align="left" rowspan="1" colspan="1">6</td>
<td align="left" rowspan="1" colspan="1">795</td>
<td align="left" rowspan="1" colspan="1">0.9% (0.4–1.9%)</td>
<td align="left" rowspan="1" colspan="1">1</td>
<td align="left" rowspan="1" colspan="1">NA</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1">Axitinib</td>
<td align="left" rowspan="1" colspan="1">4</td>
<td align="left" rowspan="1" colspan="1">20</td>
<td align="left" rowspan="1" colspan="1">535</td>
<td align="left" rowspan="1" colspan="1">4.6% (2.2–9.2%)</td>
<td align="left" rowspan="1" colspan="1">5.11 (2.04–12.8)</td>
<td align="left" rowspan="1" colspan="1">0.0005</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1">Pazopanib</td>
<td align="left" rowspan="1" colspan="1">6</td>
<td align="left" rowspan="1" colspan="1">16</td>
<td align="left" rowspan="1" colspan="1">798</td>
<td align="left" rowspan="1" colspan="1">2.2% (0.6–6.9%)</td>
<td align="left" rowspan="1" colspan="1">2.69 (1.05–6.91)</td>
<td align="left" rowspan="1" colspan="1">0.04</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1">Vandetanib</td>
<td align="left" rowspan="1" colspan="1">1</td>
<td align="left" rowspan="1" colspan="1">0</td>
<td align="left" rowspan="1" colspan="1">231</td>
<td align="left" rowspan="1" colspan="1">0%</td>
<td align="left" rowspan="1" colspan="1">0.26 (0.01–4.67)</td>
<td align="left" rowspan="1" colspan="1">0.36</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1">Regorafenib</td>
<td align="left" rowspan="1" colspan="1">1</td>
<td align="left" rowspan="1" colspan="1">7</td>
<td align="left" rowspan="1" colspan="1">500</td>
<td align="left" rowspan="1" colspan="1">1.4% (0.7–2.9%)</td>
<td align="left" rowspan="1" colspan="1">1.87 (0.62–5.59)</td>
<td align="left" rowspan="1" colspan="1">0.26</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1">Cediranib</td>
<td align="left" rowspan="1" colspan="1">5</td>
<td align="left" rowspan="1" colspan="1">5</td>
<td align="left" rowspan="1" colspan="1">186</td>
<td align="left" rowspan="1" colspan="1">3.9% (1.4–10.3%)</td>
<td align="left" rowspan="1" colspan="1">3.63 (1.10–12.03)</td>
<td align="left" rowspan="1" colspan="1">0.03</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1">Tivozanib</td>
<td align="left" rowspan="1" colspan="1">2</td>
<td align="left" rowspan="1" colspan="1">8</td>
<td align="left" rowspan="1" colspan="1">531</td>
<td align="left" rowspan="1" colspan="1">1.5% (0.8–3.1%)</td>
<td align="left" rowspan="1" colspan="1">2.01(0.69–5.83)</td>
<td align="left" rowspan="1" colspan="1">0.20</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1">Linifanib</td>
<td align="left" rowspan="1" colspan="1">3</td>
<td align="left" rowspan="1" colspan="1">14</td>
<td align="left" rowspan="1" colspan="1">236</td>
<td align="left" rowspan="1" colspan="1">6.8% (3.9–11.4%)</td>
<td align="left" rowspan="1" colspan="1">8.29 (3.15–21.83)</td>
<td align="left" rowspan="1" colspan="1">0.0001</td>
</tr>
</tbody>
</table>
</alternatives></table-wrap></sec><sec id="s3c">
<title>Incidence of high-grade proteinuria events</title>
<p>A total of 3,<italic>812</italic> patients from <italic>25</italic> trials were available for analysis. There were <italic>76</italic> high-grade proteinuria events among these patients. The highest incidence (12.7%; 95% CI, 6.2%–24.4%) as observed in a phase II trials of renal cell cancer patients treated with pazopanib <xref ref-type="bibr" rid="pone.0090135-Hainsworth1">[57]</xref> and no cases of high-grade proteinuria was observed in two trials treated with sorafenib <xref ref-type="bibr" rid="pone.0090135-Hsu1">[38]</xref>, <xref ref-type="bibr" rid="pone.0090135-Rini1">[56]</xref>, two trials treated with cediranib <xref ref-type="bibr" rid="pone.0090135-Mulders1">[54]</xref>, <xref ref-type="bibr" rid="pone.0090135-Robinson1">[71]</xref>, two trials treated with pazoapnib <xref ref-type="bibr" rid="pone.0090135-Bible1">[60]</xref>, <xref ref-type="bibr" rid="pone.0090135-Sleijfer1">[65]</xref>, one trial treated with axitinib <xref ref-type="bibr" rid="pone.0090135-Rixe1">[50]</xref>, one trial treated with vandetanib <xref ref-type="bibr" rid="pone.0090135-Wells2">[62]</xref>, and one trial treated with linifanib <xref ref-type="bibr" rid="pone.0090135-Toh1">[69]</xref>, respectively. Using a random-effects model (heterogeneity test: Q = 72.46; <italic>P</italic>&lt;<italic>0.001</italic>; <italic>I</italic><sup>2</sup> = 64%), the summary incidence of high-grade proteinuria events in patients receiving VEGFR-TKIs was 2.4% (95% CI, 1.6%–3.7%, <xref ref-type="table" rid="pone-0090135-t003">table 3</xref>).</p>
</sec><sec id="s3d">
<title>Incidence of proteinuria in patients with RCC vs. non-RCC malignancy</title>
<p>In order to explore the relationship between VEGFR-TKIs associated proteinuria and tumor types, we further analyzed the incidence of proteinuria in patients with RCC and non-RCC cancers. Among patients with RCC, the summary incidences of all grade and high grade proteinuria was 18.4% (95%CI: 11.5–28.3%) and 2.5% (95%CI:1.4–4.4%) using a random effects model; while for those patients with non-RCC malignancies, the summary incidences of all grade and high grade proteinuria were 18.5% (95%CI: 10.7–29.9%) and 2.3% (95%CI: 1.2–4.4%) using a random effects model. In addition, there was no significant difference detected between RCC and non-RCC cancer in terms of the incidence of VEGFR-TKIs-associated all grade proteinuria (RR 1.05, 95% CI 0.88, 1.25, <italic>P</italic> = 0.60) and high grade proteinuria (RR 1.26, 95% CI 0.79, 2.02, <italic>P = 0.</italic>33) (<xref ref-type="table" rid="pone-0090135-t003">table 3</xref>).</p>
</sec><sec id="s3e">
<title>Differences in proteinuria incidence among various VEGFR-TKIs</title>
<p>When stratified by each VEGFR-TKIs, the incidence of all-grade proteinuria was 11.6% (95%CI: 4.3–27.6%) for sorafenib, 20.2% (6.9–46.7%) for axitinib, 13.5% (95%CI: 3.9–37.6%) for pazopanib, 10.0% (95%CI:6.7–14.5%)vandetanib, 7.0% (95%CI: 5.1–9.6%) for regorafenib. 37.8% (95%CI: 27.5–49.3%) for cediranib, 9.6% (95%CI: 0.9–54.3%) for tivozanib, and 27.3% (95%CI, 18.6–38.1%) for linifanib, respectively. As for high-grade proteinuria, the incidence was 0.9% (95%CI: 0.4–1.9%) for sorafenib, 4.6% (2.2–9.2%) for axitinib, 2.2% (95%CI: 0.6–6.9%) for pazopanib, 0.0% for vandetanib, 1.4% (95%CI:0.7–2.9%) for regorafenib. 3.9% (95%CI: 1.4–10.3%) for cediranib, 1.5% (95%CI: 0.8–3.1%) for tivozanib, and 6.8% (95%CI, 3.9–11.4%) for linifanib, respectively (<xref ref-type="table" rid="pone-0090135-t003">table 3</xref>). The risk of developing proteinuria significantly varied among VEGFR-TKIs. Compared with sorafenib, cediranib (RR 3.45, 95%CI: 2.41–4.92, <italic>p</italic> = 0.001) and linifanib (RR 1.96, 95%CI: 1.37–2.80, <italic>p</italic> = 0.002) significantly increased the risk of developing proteinuria, while vandetanib (RR 0.62, 95%CI: 0.39–1.00, p = 0.05) and regorafenib (RR 0.42, 95%CI: 0.28–0.63, <italic>p</italic> = 0.001) significantly decreased the risk of developing proteinuria. As for high-grade proteinuria, axitinib (RR 5.11, 95%CI: 2.04–12.8, p = 0.0005), pazopanib (RR 2.69, 95%CI: 1.05–6.91, <italic>p</italic> = 0.04), cediranib (RR 3.63, 95%CI: 1.10–12.03, p = 0.03) and linifanib (RR 8.29, 3.15–21.83, p = 0.001) significantly increased the risk of developing proteinuria when compared to sorafenib (<xref ref-type="table" rid="pone-0090135-t003">table 3</xref>).</p>
</sec><sec id="s3f">
<title>Odds Ratio of proteinuria events</title>
<p>To investigate the specific contribution of VEGFR-TKIs to the development of proteinuria events and exclude the influence of confounding factors such as underlying malignancy, and other therapeutic interventions, we therefore determined the odds ratio (OR) of VEGFR-TKIs associated proteinuria events. Two phase III trials were excluded for OR analysis as both group received VEGFR-TKIs agents <xref ref-type="bibr" rid="pone.0090135-Motzer2">[53]</xref>, <xref ref-type="bibr" rid="pone.0090135-Motzer3">[58]</xref>. A total of 2,<italic>220</italic> patients in the 7 RCTs were included for calculating the OR of all-grade proteinuria events, the combined results demonstrated that the use of VEGFR-TKIs was associated with a significantly increased risk of developing all-grade proteinuria events with an OR of 2.92 (95%CI: 1.09–7.82, <italic>p</italic> = <italic>0.033</italic>, <xref ref-type="fig" rid="pone-0090135-g002"><bold>figure 2</bold></xref>) using a random-effects model (<italic>I</italic><sup>2</sup> = 65%, <italic>p</italic> = <italic>0.008</italic>). Due to significant heterogeneity among the included trials, we then performed sub-group analysis according to the quality of included trials. Our results showed that the use of VEGFR-TKIs significantly increased the risk of proteinuria in high-quality trials (OR 5.48, 95%CI: 2.49–12.03, <italic>p</italic>&lt;0.001), but not for low-quality trials (OR 1.05, 95%CI: 0.42–2.61, <italic>p</italic> = 0.92). As for high-grade proteinuria events, a total of 3,<italic>799</italic> patients in the 10 RCTs were included for analysis. The combined OR showed that the use of VEGFR-TKIs significantly increased the risk of high-grade proteinuria events among cancer patients (OR 1.97, 95%CI: 1.01–3.84, <italic>p</italic> = <italic>0.046</italic>, <xref ref-type="fig" rid="pone-0090135-g003"><bold>figure 3</bold></xref>) using a fixed effects model (<italic>I</italic><sup>2</sup> = 0%, <italic>p</italic> = <italic>0.93</italic>). We also performed sub-group analysis based on quality of included trials to investigate the potential risk difference. Again, the use of VEGFR-TKIs significantly increased the risk of high-grade proteinuria in high-quality trials (OR 3.44, 95%CI: 1.21–9.78, <italic>p</italic> = 0.02), but not for low-quality trials (OR 1.35, 95%CI: 0.57–3.19, <italic>p</italic> = 0.50).</p>
<fig id="pone-0090135-g002" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0090135.g002</object-id><label>Figure 2</label><caption>
<title>Odds ratio of all-grade proteinuria associated with VEGFR-TKIs vs control.</title>
</caption><graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pone.0090135.g002" position="float" xlink:type="simple"/></fig><fig id="pone-0090135-g003" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0090135.g003</object-id><label>Figure 3</label><caption>
<title>Odds ratio of high-grade proteinuria associated with VEGFR-TKIs vs control.</title>
</caption><graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pone.0090135.g003" position="float" xlink:type="simple"/></fig></sec><sec id="s3g">
<title>Publication bias</title>
<p>No evidence of publication bias was detected for the OR of all-grade and high-grade proteinuria events in this study by the funnel plot (<xref ref-type="fig" rid="pone-0090135-g004">figure 4</xref>), Egger's test and Begg' test (OR of all-grade proteinuria: Egger's test <italic>p</italic> = 0.09, Begg's test <italic>p</italic> = 0.76; OR of high-grade proteinuria: Egger's test <italic>p</italic> = 0.17, Begg's test <italic>p</italic> = 0.45).</p>
<fig id="pone-0090135-g004" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0090135.g004</object-id><label>Figure 4</label><caption>
<title>Funnel plot of standard error by log-odds ratio for all-grade and high-grade proteinuria.</title>
</caption><graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pone.0090135.g004" position="float" xlink:type="simple"/></fig></sec></sec><sec id="s4">
<title>Discussion</title>
<p>Although low grade proteinuria (grade 1–2) is typically asymptomatic and decreases after anti-VEGF treatment ends, serious proteinuria (grade 3–5) including nephrotic syndrome may cause significant morbidity with a possible consequence of renal failure and fatality during anti-VEGF therapy; concerns have arisen regarding the risk of proteinuria with the use of these drugs. Two previous meta-analyses have demonstrated that VEGF monoclonal antibody bevacizumab is associated with a significantly increased risk of developing proteinuria <xref ref-type="bibr" rid="pone.0090135-Zhu1">[19]</xref>, <xref ref-type="bibr" rid="pone.0090135-Wu2">[36]</xref>. In addition, the authors identify a relationship between bevacizumab dosage and proteinuria (all-grade: RR 1.4 for low dosage versus 2.2 for high dose; high-grade: RR 2.62 for low dosage versus 8.56 for high dosage) <xref ref-type="bibr" rid="pone.0090135-Wu2">[36]</xref>. And that report also demonstrates that patients with renal cell carcinoma (RCC) have significantly increased risk for developing proteinuria when compared to non RCC patients <xref ref-type="bibr" rid="pone.0090135-Wu2">[36]</xref>. However, no published article explores the association between proteinuria and VEGFR-TKIs, which also target VEGF signaling pathways. As a result, we conduct this study to investigate the overall incidence and risk of proteinuria in cancer patients treated with VEGFR-TKIs.</p>
<p>Our meta-analysis, included 6,882 patients from 33 clinical trials, demonstrates that the pooled incidence of all-grade and high-grade proteinuria is 18.7% (95% CI, 13.3%–25.6%) and 2.4% (95% CI, 1.6%–3.7%), which is higher than that of bevacizumab reported by Wu S. et al. (all-grade: 13.3%; high-grade: 2.2%) <xref ref-type="bibr" rid="pone.0090135-Wu2">[36]</xref>. We also find that the use of VEGFR-TKIs is associated with a significantly increased risk of developing all-grade (OR 2.92, 95%CI: 1.09–7.82, <italic>p</italic> = <italic>0.033</italic>) and high-grade proteinuria (OR 1.97, 95%CI: 1.01–3.84, <italic>p</italic> = <italic>0.046</italic>). As VEGFR-TKIs are increasingly used in the routine treatment of cancer patients and in the setting of clinical trials in combination with other agents, it is important that oncologists, internists, and nephrologists monitor and manage proteinuria appropriately to ensure that patients receive maximum benefit from VEGFR-TKIs therapy.</p>
<p>The pathogeneses of VEGF inhibitor-induced proteinuria are not thoroughly understood. Vitro studies have found that VEGF is constitutively produced by podocytes with a function of activating VEGF receptor 2 on glomerular capillary endothelial cells, and its inhibition may cause a loss of endothelial fenestrations and podocytes and reduced proliferation of endothelial cells <xref ref-type="bibr" rid="pone.0090135-Eremina1">[80]</xref>, <xref ref-type="bibr" rid="pone.0090135-Schrijvers1">[81]</xref>. Human and animal data suggests that proper VEGF expression is important to maintain the structure and function of the glomerulus. Overexpression or underexpression of VEGF may cause glomerulopathy. In Vuorela P et al's study <xref ref-type="bibr" rid="pone.0090135-Vuorela1">[82]</xref>, elevated levels of soluble VEGFR-1 protein, an endogenous antagonist of the VEGF pathway, are observed in the amniotic fluid of preeclamptic women. In animal studies, underexpression of VEGF results in glomerulopathy characterized by nephrotic-range proteinuria, endotheliosis, and hyaline deposits that resemble the pathological lesions seen in renal biopsy specimens from patients with preeclampsia <xref ref-type="bibr" rid="pone.0090135-KincaidSmith1">[83]</xref>. And overexpression of VEGF also leads to proteinuria from a collapsing focal segmental glomerulosclerosis, a lesion also seen with human immunodeficiency virus associated nephropathy <xref ref-type="bibr" rid="pone.0090135-Eremina1">[80]</xref>. Additionally, VEGFR-TKIs-associated proteinuria may be a consequence in part of increased intraglomerular pressure resulting from hypertension. However, hypertension may not play a major role in the development of proteinuria, because the glomerular injury from reduced VEGF expression of podocytes preceded hypertension in a murine conditional knockout model <xref ref-type="bibr" rid="pone.0090135-Eremina2">[84]</xref>.</p>
<p>Adequate and aggressive management of severe proteinuria could be essential for many patients, because severe proteinuria is an independent risk factor for renal disease. However, there are no evidence-based guidelines for the management of VEGFR-TKIs-associated proteinuria. According to the manufacturer package insert for pazopanib and axitinib <xref ref-type="bibr" rid="pone.0090135-US1">[85]</xref>, <xref ref-type="bibr" rid="pone.0090135-US2">[86]</xref>, baseline and periodic urinalysis during treatment is recommended with follow up measurement of 24-hour urine protein as clinically indicated. Interrupt VEGFR-TKIs and dose reduce for 24-hour urine protein ≥3 grams; discontinue VEGFR-TKIs for repeat episodes despite dose reductions. Additionally, blockade of the renin-angiotension system may have specific benefit in those hypertensive patients with proteinuria, thus it is reasonable to initiate angiotension converting enzyme inhibitors (ACEI) or angiotension receptor blockers (ARB) as first-line therapy for anti-VEGF-targeted patients with hypertension and proteinuria <xref ref-type="bibr" rid="pone.0090135-1">[87]</xref>, although this remains to be validated in randomized, controlled studies.</p>
<p>Meta-analysis is considered as a useful tool for analyzing rare and unintended effects of a treatment because it could allow synthesis of data and achieve more stable estimates of effects. However, there are several limitations needed to be considered. First, our findings are influenced by the limitation of individual trials included in the analysis, such as the use of dipstick assessment for proteinuria, no specification of nephrotic syndrome for National Cancer Institute's Common Terminology Criteria grading, and completeness of follow-up; baseline proteinuria is also not mentioned in these trials. Secondly, this is a meta-analysis at study level; therefore we do not have access to individual patient data. Thus we could not establish risk factors associated with the development of proteinuria. Nevertheless, it is important to point out that meta-analysis from individual patients data can also carry bias, as data may only be available to limited numbers of research groups. Third, although proteinuria events are prospectively collected for each individual study, this analysis is retrospective, and there are potentially important differences among the studies, including differing tumor types, dosage and administration schedule of VEGFR-TKIs, periods of study conduct and study investigators. All of these would increase the clinical heterogeneity among included trials, which also make the interpretation of a meta-analysis more problematic. Finally, all these studies exclude patients with poor renal, hematological, and hepatic functions, and are performed mostly at major academic centers and research institutions; the analysis of these studies may not apply to patients with organ dysfunctions and in the community, and the overall incidences of proteinuria from this study may be overestimated.</p>
</sec><sec id="s5">
<title>Conclusions</title>
<p>In summary, the current meta-analysis suggests that the use of VEGFR-TKIs significantly increase the risk of developing proteinuria in cancer patients. As this class of drugs is used increasingly in patients with metastatic cancers, physicians should be aware of this adverse effect and should monitor cancer patients receiving VEGFR-TKIs. Further studies are recommended to focus on uncovering the mechanisms of VEGFR-TKIs-induced proteinuria, as well as investigating risk differences among different VEGFR-TKIs and tumor types.</p>
</sec><sec id="s6">
<title>Supporting Information</title>
<supplementary-material id="pone.0090135.s001" mimetype="application/msword" xlink:href="info:doi/10.1371/journal.pone.0090135.s001" position="float" xlink:type="simple"><label>Checklist S1</label><caption>
<p><bold>PRISMA Checklist.</bold></p>
<p>(DOC)</p>
</caption></supplementary-material></sec></body>
<back><ref-list>
<title>References</title>
<ref id="pone.0090135-Folkman1"><label>1</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Folkman</surname><given-names>J</given-names></name> (<year>1971</year>) <article-title>Tumor angiogenesis: therapeutic implications</article-title>. <source>N Engl J Med</source> <volume>285</volume>: <fpage>1182</fpage>–<lpage>1186</lpage>.</mixed-citation>
</ref>
<ref id="pone.0090135-Sherwood1"><label>2</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Sherwood</surname><given-names>LM</given-names></name>, <name name-style="western"><surname>Parris</surname><given-names>EE</given-names></name>, <name name-style="western"><surname>Folkman</surname><given-names>J</given-names></name> (<year>1971</year>) <article-title>Tumor angiogenesis: therapeutic implications</article-title>. <source>New England Journal of Medicine</source> <volume>285</volume>: <fpage>1182</fpage>–<lpage>1186</lpage>.</mixed-citation>
</ref>
<ref id="pone.0090135-Weidner1"><label>3</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Weidner</surname><given-names>N</given-names></name>, <name name-style="western"><surname>Semple</surname><given-names>JP</given-names></name>, <name name-style="western"><surname>Welch</surname><given-names>WR</given-names></name>, <name name-style="western"><surname>Folkman</surname><given-names>J</given-names></name> (<year>1991</year>) <article-title>Tumor angiogenesis and metastasis–correlation in invasive breast carcinoma</article-title>. <source>N Engl J Med</source> <volume>324</volume>: <fpage>1</fpage>–<lpage>8</lpage>.</mixed-citation>
</ref>
<ref id="pone.0090135-Folkman2"><label>4</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Folkman</surname><given-names>J</given-names></name> (<year>1995</year>) <article-title>Angiogenesis in cancer, vascular, rheumatoid and other disease</article-title>. <source>Nat Med</source> <volume>1</volume>: <fpage>27</fpage>–<lpage>31</lpage>.</mixed-citation>
</ref>
<ref id="pone.0090135-Zetter1"><label>5</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Zetter</surname><given-names>BR</given-names></name> (<year>1998</year>) <article-title>Angiogenesis and tumor metastasis</article-title>. <source>Annual review of medicine</source> <volume>49</volume>: <fpage>407</fpage>–<lpage>424</lpage>.</mixed-citation>
</ref>
<ref id="pone.0090135-Carmeliet1"><label>6</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Carmeliet</surname><given-names>P</given-names></name>, <name name-style="western"><surname>Jain</surname><given-names>RK</given-names></name> (<year>2000</year>) <article-title>Angiogenesis in cancer and other diseases</article-title>. <source>Nature</source> <volume>407</volume>: <fpage>249</fpage>–<lpage>257</lpage>.</mixed-citation>
</ref>
<ref id="pone.0090135-Ferrara1"><label>7</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Ferrara</surname><given-names>N</given-names></name>, <name name-style="western"><surname>Hillan</surname><given-names>KJ</given-names></name>, <name name-style="western"><surname>Gerber</surname><given-names>HP</given-names></name>, <name name-style="western"><surname>Novotny</surname><given-names>W</given-names></name> (<year>2004</year>) <article-title>Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer</article-title>. <source>Nat Rev Drug Discov</source> <volume>3</volume>: <fpage>391</fpage>–<lpage>400</lpage>.</mixed-citation>
</ref>
<ref id="pone.0090135-Carmeliet2"><label>8</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Carmeliet</surname><given-names>P</given-names></name> (<year>2005</year>) <article-title>VEGF as a key mediator of angiogenesis in cancer</article-title>. <source>Oncology</source> <volume>69 Suppl 3</volume>: <fpage>4</fpage>–<lpage>10</lpage>.</mixed-citation>
</ref>
<ref id="pone.0090135-Aghajanian1"><label>9</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Aghajanian</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Blank</surname><given-names>SV</given-names></name>, <name name-style="western"><surname>Goff</surname><given-names>BA</given-names></name>, <name name-style="western"><surname>Judson</surname><given-names>PL</given-names></name>, <name name-style="western"><surname>Teneriello</surname><given-names>MG</given-names></name>, <etal>et al</etal>. (<year>2012</year>) <article-title>OCEANS: a randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer</article-title>. <source>J Clin Oncol</source> <volume>30</volume>: <fpage>2039</fpage>–<lpage>2045</lpage>.</mixed-citation>
</ref>
<ref id="pone.0090135-Gianni1"><label>10</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Gianni</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Romieu</surname><given-names>GH</given-names></name>, <name name-style="western"><surname>Lichinitser</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Serrano</surname><given-names>SV</given-names></name>, <name name-style="western"><surname>Mansutti</surname><given-names>M</given-names></name>, <etal>et al</etal>. (<year>2013</year>) <article-title>AVEREL: A Randomized Phase III Trial Evaluating Bevacizumab in Combination With Docetaxel and Trastuzumab as First-Line Therapy for HER2-Positive Locally Recurrent/Metastatic Breast Cancer</article-title>. <source>J Clin Oncol</source> <volume>31</volume>: <fpage>1719</fpage>–<lpage>1725</lpage>.</mixed-citation>
</ref>
<ref id="pone.0090135-Qi1"><label>11</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Qi</surname><given-names>WX</given-names></name>, <name name-style="western"><surname>Tang</surname><given-names>LN</given-names></name>, <name name-style="western"><surname>He</surname><given-names>AN</given-names></name>, <name name-style="western"><surname>Shen</surname><given-names>Z</given-names></name>, <name name-style="western"><surname>Yao</surname><given-names>Y</given-names></name> (<year>2011</year>) <article-title>The role of vandetanib in the second-line treatment for advanced non-small-cell-lung cancer: a meta-analysis of four randomized controlled trials</article-title>. <source>Lung</source> <volume>189</volume>: <fpage>437</fpage>–<lpage>443</lpage>.</mixed-citation>
</ref>
<ref id="pone.0090135-Wells1"><label>12</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Wells</surname><given-names>SA</given-names></name>, <name name-style="western"><surname>Gosnell</surname><given-names>JE</given-names></name>, <name name-style="western"><surname>Gagel</surname><given-names>RF</given-names></name>, <name name-style="western"><surname>Moley</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Pfister</surname><given-names>D</given-names></name>, <etal>et al</etal>. (<year>2010</year>) <article-title>Vandetanib for the Treatment of Patients With Locally Advanced or Metastatic Hereditary Medullary Thyroid Cancer</article-title>. <source>JOURNAL OF CLINICAL ONCOLOGY</source> <volume>28</volume>: <fpage>767</fpage>–<lpage>772</lpage>.</mixed-citation>
</ref>
<ref id="pone.0090135-Sternberg1"><label>13</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Sternberg</surname><given-names>CN</given-names></name>, <name name-style="western"><surname>Davis</surname><given-names>ID</given-names></name>, <name name-style="western"><surname>Mardiak</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Szczylik</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Lee</surname><given-names>E</given-names></name>, <etal>et al</etal>. (<year>2010</year>) <article-title>Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial</article-title>. <source>J Clin Oncol</source> <volume>28</volume>: <fpage>1061</fpage>–<lpage>1068</lpage>.</mixed-citation>
</ref>
<ref id="pone.0090135-Escudier1"><label>14</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Escudier</surname><given-names>B</given-names></name>, <name name-style="western"><surname>Eisen</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Stadler</surname><given-names>WM</given-names></name>, <name name-style="western"><surname>Szczylik</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Oudard</surname><given-names>S</given-names></name>, <etal>et al</etal>. (<year>2007</year>) <article-title>Sorafenib in advanced clear-cell renal-cell carcinoma</article-title>. <source>N Engl J Med</source> <volume>356</volume>: <fpage>125</fpage>–<lpage>134</lpage>.</mixed-citation>
</ref>
<ref id="pone.0090135-Llovet1"><label>15</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Llovet</surname><given-names>JM</given-names></name>, <name name-style="western"><surname>Ricci</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Mazzaferro</surname><given-names>V</given-names></name>, <name name-style="western"><surname>Hilgard</surname><given-names>P</given-names></name>, <name name-style="western"><surname>Gane</surname><given-names>E</given-names></name>, <etal>et al</etal>. (<year>2008</year>) <article-title>Sorafenib in advanced hepatocellular carcinoma</article-title>. <source>N Engl J Med</source> <volume>359</volume>: <fpage>378</fpage>–<lpage>390</lpage>.</mixed-citation>
</ref>
<ref id="pone.0090135-Motzer1"><label>16</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Motzer</surname><given-names>RJ</given-names></name>, <name name-style="western"><surname>Hutson</surname><given-names>TE</given-names></name>, <name name-style="western"><surname>Tomczak</surname><given-names>P</given-names></name>, <name name-style="western"><surname>Michaelson</surname><given-names>MD</given-names></name>, <name name-style="western"><surname>Bukowski</surname><given-names>RM</given-names></name>, <etal>et al</etal>. (<year>2007</year>) <article-title>Sunitinib versus interferon alfa in metastatic renal-cell carcinoma</article-title>. <source>N Engl J Med</source> <volume>356</volume>: <fpage>115</fpage>–<lpage>124</lpage>.</mixed-citation>
</ref>
<ref id="pone.0090135-Raymond1"><label>17</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Raymond</surname><given-names>E</given-names></name>, <name name-style="western"><surname>Dahan</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Raoul</surname><given-names>JL</given-names></name>, <name name-style="western"><surname>Bang</surname><given-names>YJ</given-names></name>, <name name-style="western"><surname>Borbath</surname><given-names>I</given-names></name>, <etal>et al</etal>. (<year>2011</year>) <article-title>Sunitinib malate for the treatment of pancreatic neuroendocrine tumors</article-title>. <source>N Engl J Med</source> <volume>364</volume>: <fpage>501</fpage>–<lpage>513</lpage>.</mixed-citation>
</ref>
<ref id="pone.0090135-Scappaticci1"><label>18</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Scappaticci</surname><given-names>FA</given-names></name>, <name name-style="western"><surname>Skillings</surname><given-names>JR</given-names></name>, <name name-style="western"><surname>Holden</surname><given-names>SN</given-names></name>, <name name-style="western"><surname>Gerber</surname><given-names>HP</given-names></name>, <name name-style="western"><surname>Miller</surname><given-names>K</given-names></name>, <etal>et al</etal>. (<year>2007</year>) <article-title>Arterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumab</article-title>. <source>J Natl Cancer Inst</source> <volume>99</volume>: <fpage>1232</fpage>–<lpage>1239</lpage>.</mixed-citation>
</ref>
<ref id="pone.0090135-Zhu1"><label>19</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Zhu</surname><given-names>X</given-names></name>, <name name-style="western"><surname>Wu</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Dahut</surname><given-names>WL</given-names></name>, <name name-style="western"><surname>Parikh</surname><given-names>CR</given-names></name> (<year>2007</year>) <article-title>Risks of proteinuria and hypertension with bevacizumab, an antibody against vascular endothelial growth factor: systematic review and meta-analysis</article-title>. <source>Am J Kidney Dis</source> <volume>49</volume>: <fpage>186</fpage>–<lpage>193</lpage>.</mixed-citation>
</ref>
<ref id="pone.0090135-Nalluri1"><label>20</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Nalluri</surname><given-names>SR</given-names></name>, <name name-style="western"><surname>Chu</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Keresztes</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Zhu</surname><given-names>X</given-names></name>, <name name-style="western"><surname>Wu</surname><given-names>S</given-names></name> (<year>2008</year>) <article-title>Risk of venous thromboembolism with the angiogenesis inhibitor bevacizumab in cancer patients: a meta-analysis</article-title>. <source>JAMA</source> <volume>300</volume>: <fpage>2277</fpage>–<lpage>2285</lpage>.</mixed-citation>
</ref>
<ref id="pone.0090135-Hapani1"><label>21</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Hapani</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Chu</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Wu</surname><given-names>S</given-names></name> (<year>2009</year>) <article-title>Risk of gastrointestinal perforation in patients with cancer treated with bevacizumab: a meta-analysis</article-title>. <source>Lancet Oncol</source> <volume>10</volume>: <fpage>559</fpage>–<lpage>568</lpage>.</mixed-citation>
</ref>
<ref id="pone.0090135-Je1"><label>22</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Je</surname><given-names>Y</given-names></name>, <name name-style="western"><surname>Schutz</surname><given-names>FA</given-names></name>, <name name-style="western"><surname>Choueiri</surname><given-names>TK</given-names></name> (<year>2009</year>) <article-title>Risk of bleeding with vascular endothelial growth factor receptor tyrosine-kinase inhibitors sunitinib and sorafenib: a systematic review and meta-analysis of clinical trials</article-title>. <source>Lancet Oncol</source> <volume>10</volume>: <fpage>967</fpage>–<lpage>974</lpage>.</mixed-citation>
</ref>
<ref id="pone.0090135-Choueiri1"><label>23</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Choueiri</surname><given-names>TK</given-names></name>, <name name-style="western"><surname>Schutz</surname><given-names>FA</given-names></name>, <name name-style="western"><surname>Je</surname><given-names>Y</given-names></name>, <name name-style="western"><surname>Rosenberg</surname><given-names>JE</given-names></name>, <name name-style="western"><surname>Bellmunt</surname><given-names>J</given-names></name> (<year>2010</year>) <article-title>Risk of arterial thromboembolic events with sunitinib and sorafenib: a systematic review and meta-analysis of clinical trials</article-title>. <source>J Clin Oncol</source> <volume>28</volume>: <fpage>2280</fpage>–<lpage>2285</lpage>.</mixed-citation>
</ref>
<ref id="pone.0090135-Qi2"><label>24</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Qi</surname><given-names>WX</given-names></name>, <name name-style="western"><surname>Min</surname><given-names>DL</given-names></name>, <name name-style="western"><surname>Shen</surname><given-names>Z</given-names></name>, <name name-style="western"><surname>Sun</surname><given-names>YJ</given-names></name>, <name name-style="western"><surname>Lin</surname><given-names>F</given-names></name>, <etal>et al</etal>. (<year>2012</year>) <article-title>Risk of venous thromboembolic events associated with VEGFR-TKIs: A systematic review and meta-analysis</article-title>. <source>Int J Cancer</source> <volume>132</volume>: <fpage>2967</fpage>–<lpage>2974</lpage>.</mixed-citation>
</ref>
<ref id="pone.0090135-Qi3"><label>25</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Qi</surname><given-names>WX</given-names></name>, <name name-style="western"><surname>Lin</surname><given-names>F</given-names></name>, <name name-style="western"><surname>Sun</surname><given-names>YJ</given-names></name>, <name name-style="western"><surname>Tang</surname><given-names>LN</given-names></name>, <name name-style="western"><surname>He</surname><given-names>AN</given-names></name>, <etal>et al</etal>. (<year>2013</year>) <article-title>Incidence and risk of hypertension with pazopanib in patients with cancer: a meta-analysis</article-title>. <source>Cancer Chemother Pharmacol</source> <volume>71</volume>: <fpage>431</fpage>–<lpage>439</lpage>.</mixed-citation>
</ref>
<ref id="pone.0090135-Qi4"><label>26</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Qi</surname><given-names>WX</given-names></name>, <name name-style="western"><surname>He</surname><given-names>AN</given-names></name>, <name name-style="western"><surname>Shen</surname><given-names>Z</given-names></name>, <name name-style="western"><surname>Yao</surname><given-names>Y</given-names></name> (<year>2013</year>) <article-title>Incidence and risk of hypertension with a novel multi-targeted kinase inhibitor axitinib in cancer patients: a systematic review and meta-analysis</article-title>. <source>Br J Clin Pharmacol</source> <volume>76</volume>: <fpage>348</fpage>–<lpage>357</lpage>.</mixed-citation>
</ref>
<ref id="pone.0090135-Qi5"><label>27</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Qi</surname><given-names>WX</given-names></name>, <name name-style="western"><surname>Shen</surname><given-names>Z</given-names></name>, <name name-style="western"><surname>Lin</surname><given-names>F</given-names></name>, <name name-style="western"><surname>Sun</surname><given-names>YJ</given-names></name>, <name name-style="western"><surname>Min</surname><given-names>DL</given-names></name>, <etal>et al</etal>. (<year>2013</year>) <article-title>Incidence and Risk of Hypertension with Vandetanib in Cancer Patients: A Systematic review and Meta-analysis of clinical trials</article-title>. <source>Br J Clin Pharmacol</source> <volume>75</volume>: <fpage>919</fpage>–<lpage>930</lpage>.</mixed-citation>
</ref>
<ref id="pone.0090135-Ibrahim1"><label>28</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Ibrahim</surname><given-names>EM</given-names></name>, <name name-style="western"><surname>Kazkaz</surname><given-names>GA</given-names></name>, <name name-style="western"><surname>Abouelkhair</surname><given-names>KM</given-names></name>, <name name-style="western"><surname>Bayer</surname><given-names>AM</given-names></name>, <name name-style="western"><surname>Elmasri</surname><given-names>OA</given-names></name> (<year>2013</year>) <article-title>Sunitinib adverse events in metastatic renal cell carcinoma: a meta-analysis</article-title>. <source>Int J Clin Oncol</source> <volume>18</volume>: <fpage>1060</fpage>–<lpage>1069</lpage>.</mixed-citation>
</ref>
<ref id="pone.0090135-Cortes1"><label>29</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Cortes</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Calvo</surname><given-names>V</given-names></name>, <name name-style="western"><surname>Ramirez-Merino</surname><given-names>N</given-names></name>, <name name-style="western"><surname>O'Shaughnessy</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Brufsky</surname><given-names>A</given-names></name>, <etal>et al</etal>. (<year>2012</year>) <article-title>Adverse events risk associated with bevacizumab addition to breast cancer chemotherapy: a meta-analysis</article-title>. <source>Ann Oncol</source> <volume>23</volume>: <fpage>1130</fpage>–<lpage>1137</lpage>.</mixed-citation>
</ref>
<ref id="pone.0090135-Qi6"><label>30</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Qi</surname><given-names>WX</given-names></name>, <name name-style="western"><surname>Sun</surname><given-names>YJ</given-names></name>, <name name-style="western"><surname>Tang</surname><given-names>LN</given-names></name>, <name name-style="western"><surname>Shen</surname><given-names>Z</given-names></name>, <name name-style="western"><surname>Yao</surname><given-names>Y</given-names></name> (<year>2014</year>) <article-title>Risk of gastrointestinal perforation in cancer patients treated with vascular endothelial growth factor receptor tyrosine kinase inhibitors: A systematic review and meta-analysis</article-title>. <source>Crit Rev Oncol Hematol</source> <volume>89</volume>: <fpage>394</fpage>–<lpage>403</lpage>.</mixed-citation>
</ref>
<ref id="pone.0090135-Qi7"><label>31</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Qi</surname><given-names>WX</given-names></name>, <name name-style="western"><surname>Tang</surname><given-names>LN</given-names></name>, <name name-style="western"><surname>Sun</surname><given-names>YJ</given-names></name>, <name name-style="western"><surname>He</surname><given-names>AN</given-names></name>, <name name-style="western"><surname>Lin</surname><given-names>F</given-names></name>, <etal>et al</etal>. (<year>2013</year>) <article-title>Incidence and risk of hemorrhagic events with vascular endothelial growth factor receptor tyrosine-kinase inhibitors: an up-to-date meta-analysis of 27 randomized controlled trials</article-title>. <source>Ann Oncol</source> <volume>24</volume>: <fpage>2943</fpage>–<lpage>2952</lpage>.</mixed-citation>
</ref>
<ref id="pone.0090135-Wu1"><label>32</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Wu</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Chen</surname><given-names>JJ</given-names></name>, <name name-style="western"><surname>Kudelka</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Lu</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Zhu</surname><given-names>X</given-names></name> (<year>2008</year>) <article-title>Incidence and risk of hypertension with sorafenib in patients with cancer: a systematic review and meta-analysis</article-title>. <source>Lancet Oncol</source> <volume>9</volume>: <fpage>117</fpage>–<lpage>123</lpage>.</mixed-citation>
</ref>
<ref id="pone.0090135-Funakoshi1"><label>33</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Funakoshi</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Latif</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Galsky</surname><given-names>MD</given-names></name> (<year>2013</year>) <article-title>Risk of hypertension in cancer patients treated with sorafenib: an updated systematic review and meta-analysis</article-title>. <source>J Hum Hypertens</source> <volume>27</volume>: <fpage>601</fpage>–<lpage>611</lpage>.</mixed-citation>
</ref>
<ref id="pone.0090135-Hurwitz1"><label>34</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Hurwitz</surname><given-names>HI</given-names></name>, <name name-style="western"><surname>Saltz</surname><given-names>LB</given-names></name>, <name name-style="western"><surname>Van Cutsem</surname><given-names>E</given-names></name>, <name name-style="western"><surname>Cassidy</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Wiedemann</surname><given-names>J</given-names></name>, <etal>et al</etal>. (<year>2011</year>) <article-title>Venous thromboembolic events with chemotherapy plus bevacizumab: a pooled analysis of patients in randomized phase II and III studies</article-title>. <source>J Clin Oncol</source> <volume>29</volume>: <fpage>1757</fpage>–<lpage>1764</lpage>.</mixed-citation>
</ref>
<ref id="pone.0090135-Sonpavde1"><label>35</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Sonpavde</surname><given-names>G</given-names></name>, <name name-style="western"><surname>Je</surname><given-names>Y</given-names></name>, <name name-style="western"><surname>Schutz</surname><given-names>F</given-names></name>, <name name-style="western"><surname>Galsky</surname><given-names>MD</given-names></name>, <name name-style="western"><surname>Paluri</surname><given-names>R</given-names></name>, <etal>et al</etal>. (<year>2013</year>) <article-title>Venous thromboembolic events with vascular endothelial growth factor receptor tyrosine kinase inhibitors: A systematic review and meta-analysis of randomized clinical trials</article-title>. <source>Crit Rev Oncol Hematol</source> <volume>87</volume>: <fpage>80</fpage>–<lpage>89</lpage>.</mixed-citation>
</ref>
<ref id="pone.0090135-Wu2"><label>36</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Wu</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Kim</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Baer</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Zhu</surname><given-names>X</given-names></name> (<year>2010</year>) <article-title>Bevacizumab increases risk for severe proteinuria in cancer patients</article-title>. <source>J Am Soc Nephrol</source> <volume>21</volume>: <fpage>1381</fpage>–<lpage>1389</lpage>.</mixed-citation>
</ref>
<ref id="pone.0090135-LaunayVacher1"><label>37</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Launay-Vacher</surname><given-names>V</given-names></name>, <name name-style="western"><surname>Deray</surname><given-names>G</given-names></name> (<year>2009</year>) <article-title>Hypertension and proteinuria: a class-effect of antiangiogenic therapies</article-title>. <source>Anticancer Drugs</source> <volume>20</volume>: <fpage>81</fpage>–<lpage>82</lpage>.</mixed-citation>
</ref>
<ref id="pone.0090135-Hsu1"><label>38</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Hsu</surname><given-names>CH</given-names></name>, <name name-style="western"><surname>Shen</surname><given-names>YC</given-names></name>, <name name-style="western"><surname>Lin</surname><given-names>ZZ</given-names></name>, <name name-style="western"><surname>Chen</surname><given-names>PJ</given-names></name>, <name name-style="western"><surname>Shao</surname><given-names>YY</given-names></name>, <etal>et al</etal>. (<year>2010</year>) <article-title>Phase II study of combining sorafenib with metronomic tegafur/uracil for advanced hepatocellular carcinoma</article-title>. <source>J Hepatol</source> <volume>53</volume>: <fpage>126</fpage>–<lpage>131</lpage>.</mixed-citation>
</ref>
<ref id="pone.0090135-Tomita1"><label>39</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Tomita</surname><given-names>Y</given-names></name>, <name name-style="western"><surname>Uemura</surname><given-names>H</given-names></name>, <name name-style="western"><surname>Fujimoto</surname><given-names>H</given-names></name>, <name name-style="western"><surname>Kanayama</surname><given-names>HO</given-names></name>, <name name-style="western"><surname>Shinohara</surname><given-names>N</given-names></name>, <etal>et al</etal>. (<year>2011</year>) <article-title>Key predictive factors of axitinib (AG-013736)-induced proteinuria and efficacy: a phase II study in Japanese patients with cytokine-refractory metastatic renal cell Carcinoma</article-title>. <source>Eur J Cancer</source> <volume>47</volume>: <fpage>2592</fpage>–<lpage>2602</lpage>.</mixed-citation>
</ref>
<ref id="pone.0090135-Kuei1"><label>40</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Kuei</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Wu</surname><given-names>S</given-names></name> (<year>2013</year>) <article-title>The risk of proteinuria with the angiogenesis inhibitor axitinib in patients with cancer</article-title>. <source>J Clin Oncol</source> <volume>31</volume>: <fpage>abstr 439</fpage>.</mixed-citation>
</ref>
<ref id="pone.0090135-Moher1"><label>41</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Moher</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Liberati</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Tetzlaff</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Altman</surname><given-names>DG</given-names></name> (<year>2009</year>) <article-title>Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement</article-title>. <source>BMJ</source> <volume>339</volume>: <fpage>b2535</fpage>.</mixed-citation>
</ref>
<ref id="pone.0090135-Moher2"><label>42</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Moher</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Liberati</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Tetzlaff</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Altman</surname><given-names>DG</given-names></name>, <name name-style="western"><surname>Group</surname><given-names>P</given-names></name> (<year>2009</year>) <article-title>Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement</article-title>. <source>PLoS Med</source> <volume>6</volume>: <fpage>e1000097</fpage>.</mixed-citation>
</ref>
<ref id="pone.0090135-NCI1"><label>43</label>
<mixed-citation publication-type="other" xlink:type="simple">NCI, Cancer Therapy Evaluation Program. CTC v 2.0 and common terminology criteria for adverse events criteria V3.0 (CTCAE). Available: <ext-link ext-link-type="uri" xlink:href="http://ctepcancergov/protocolDevelopment/electronic_applications/ctchtm" xlink:type="simple">http://ctepcancergov/protocolDevelopment/electronic_applications/ctchtm</ext-link>. Assessed 2013 January 27.</mixed-citation>
</ref>
<ref id="pone.0090135-Sweeting1"><label>44</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Sweeting</surname><given-names>MJ</given-names></name>, <name name-style="western"><surname>Sutton</surname><given-names>AJ</given-names></name>, <name name-style="western"><surname>Lambert</surname><given-names>PC</given-names></name> (<year>2004</year>) <article-title>What to add to nothing? Use and avoidance of continuity corrections in meta-analysis of sparse data</article-title>. <source>Stat Med</source> <volume>23</volume>: <fpage>1351</fpage>–<lpage>1375</lpage>.</mixed-citation>
</ref>
<ref id="pone.0090135-Zintzaras1"><label>45</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Zintzaras</surname><given-names>E</given-names></name>, <name name-style="western"><surname>Ioannidis</surname><given-names>JP</given-names></name> (<year>2005</year>) <article-title>Heterogeneity testing in meta-analysis of genome searches</article-title>. <source>Genet Epidemiol</source> <volume>28</volume>: <fpage>123</fpage>–<lpage>137</lpage>.</mixed-citation>
</ref>
<ref id="pone.0090135-Moher3"><label>46</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Moher</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Pham</surname><given-names>B</given-names></name>, <name name-style="western"><surname>Jones</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Cook</surname><given-names>DJ</given-names></name>, <name name-style="western"><surname>Jadad</surname><given-names>AR</given-names></name>, <etal>et al</etal>. (<year>1998</year>) <article-title>Does quality of reports of randomised trials affect estimates of intervention efficacy reported in meta-analyses</article-title>? <source>Lancet</source> <volume>352</volume>: <fpage>609</fpage>–<lpage>613</lpage>.</mixed-citation>
</ref>
<ref id="pone.0090135-Yusuf1"><label>47</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Yusuf</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Peto</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Lewis</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Collins</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Sleight</surname><given-names>P</given-names></name> (<year>1985</year>) <article-title>Beta blockade during and after myocardial infarction: an overview of the randomized trials</article-title>. <source>Prog Cardiovasc Dis</source> <volume>27</volume>: <fpage>335</fpage>–<lpage>371</lpage>.</mixed-citation>
</ref>
<ref id="pone.0090135-Begg1"><label>48</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Begg</surname><given-names>CB</given-names></name>, <name name-style="western"><surname>Mazumdar</surname><given-names>M</given-names></name> (<year>1994</year>) <article-title>Operating characteristics of a rank correlation test for publication bias</article-title>. <source>Biometrics</source> <volume>50</volume>: <fpage>1088</fpage>–<lpage>1101</lpage>.</mixed-citation>
</ref>
<ref id="pone.0090135-Mayer1"><label>49</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Mayer</surname><given-names>EL</given-names></name>, <name name-style="western"><surname>Dhakil</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Patel</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Sundaram</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Fabian</surname><given-names>C</given-names></name>, <etal>et al</etal>. (<year>2010</year>) <article-title>SABRE-B: an evaluation of paclitaxel and bevacizumab with or without sunitinib as first-line treatment of metastatic breast cancer</article-title>. <source>Ann Oncol</source> <volume>21</volume>: <fpage>2370</fpage>–<lpage>2376</lpage>.</mixed-citation>
</ref>
<ref id="pone.0090135-Rixe1"><label>50</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Rixe</surname><given-names>O</given-names></name>, <name name-style="western"><surname>Bukowski</surname><given-names>RM</given-names></name>, <name name-style="western"><surname>Michaelson</surname><given-names>MD</given-names></name>, <name name-style="western"><surname>Wilding</surname><given-names>G</given-names></name>, <name name-style="western"><surname>Hudes</surname><given-names>GR</given-names></name>, <etal>et al</etal>. (<year>2007</year>) <article-title>Axitinib treatment in patients with cytokine-refractory metastatic renal-cell cancer: a phase II study</article-title>. <source>Lancet Oncol</source> <volume>8</volume>: <fpage>975</fpage>–<lpage>984</lpage>.</mixed-citation>
</ref>
<ref id="pone.0090135-Jonasch1"><label>51</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Jonasch</surname><given-names>E</given-names></name>, <name name-style="western"><surname>Corn</surname><given-names>P</given-names></name>, <name name-style="western"><surname>Pagliaro</surname><given-names>LC</given-names></name>, <name name-style="western"><surname>Warneke</surname><given-names>CL</given-names></name>, <name name-style="western"><surname>Johnson</surname><given-names>MM</given-names></name>, <etal>et al</etal>. (<year>2010</year>) <article-title>Upfront, randomized, phase 2 trial of sorafenib versus sorafenib and low-dose interferon alfa in patients with advanced renal cell carcinoma: clinical and biomarker analysis</article-title>. <source>Cancer</source> <volume>116</volume>: <fpage>57</fpage>–<lpage>65</lpage>.</mixed-citation>
</ref>
<ref id="pone.0090135-Tannir1"><label>52</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Tannir</surname><given-names>NM</given-names></name>, <name name-style="western"><surname>Wong</surname><given-names>YN</given-names></name>, <name name-style="western"><surname>Kollmannsberger</surname><given-names>CK</given-names></name>, <name name-style="western"><surname>Ernstoff</surname><given-names>MS</given-names></name>, <name name-style="western"><surname>Perry</surname><given-names>DJ</given-names></name>, <etal>et al</etal>. (<year>2011</year>) <article-title>Phase 2 trial of linifanib (ABT-869) in patients with advanced renal cell cancer after sunitinib failure</article-title>. <source>Eur J Cancer</source> <volume>47</volume>: <fpage>2706</fpage>–<lpage>2714</lpage>.</mixed-citation>
</ref>
<ref id="pone.0090135-Motzer2"><label>53</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Motzer</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Nosov</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Eisen</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Bondarenko</surname><given-names>I</given-names></name>, <name name-style="western"><surname>Lesovoy</surname><given-names>V</given-names></name>, <etal>et al</etal>. (<year>2013</year>) <article-title>Tivozanib versus sorafenib as initial targeted therapy for patients with advanced renal cell carcinoma: Results from a Phase III randomized, open-label, multicenter trial</article-title>. <source>J Clin Oncol</source> <volume>31</volume>: <fpage>3791</fpage>–<lpage>3799</lpage>.</mixed-citation>
</ref>
<ref id="pone.0090135-Mulders1"><label>54</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Mulders</surname><given-names>P</given-names></name>, <name name-style="western"><surname>Hawkins</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Nathan</surname><given-names>P</given-names></name>, <name name-style="western"><surname>de Jong</surname><given-names>I</given-names></name>, <name name-style="western"><surname>Osanto</surname><given-names>S</given-names></name>, <etal>et al</etal>. (<year>2012</year>) <article-title>Cediranib monotherapy in patients with advanced renal cell carcinoma: results of a randomised phase II study</article-title>. <source>Eur J Cancer</source> <volume>48</volume>: <fpage>527</fpage>–<lpage>537</lpage>.</mixed-citation>
</ref>
<ref id="pone.0090135-Nosov1"><label>55</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Nosov</surname><given-names>DA</given-names></name>, <name name-style="western"><surname>Esteves</surname><given-names>B</given-names></name>, <name name-style="western"><surname>Lipatov</surname><given-names>ON</given-names></name>, <name name-style="western"><surname>Lyulko</surname><given-names>AA</given-names></name>, <name name-style="western"><surname>Anischenko</surname><given-names>AA</given-names></name>, <etal>et al</etal>. (<year>2012</year>) <article-title>Antitumor activity and safety of tivozanib (AV-951) in a phase II randomized discontinuation trial in patients with renal cell carcinoma</article-title>. <source>J Clin Oncol</source> <volume>30</volume>: <fpage>1678</fpage>–<lpage>1685</lpage>.</mixed-citation>
</ref>
<ref id="pone.0090135-Rini1"><label>56</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Rini</surname><given-names>B</given-names></name>, <name name-style="western"><surname>Szczylik</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Tannir</surname><given-names>NM</given-names></name>, <name name-style="western"><surname>Koralewski</surname><given-names>P</given-names></name>, <name name-style="western"><surname>Tomczak</surname><given-names>P</given-names></name>, <etal>et al</etal>. (<year>2012</year>) <article-title>AMG 386 in combination with sorafenib in patients with metastatic clear cell carcinoma of the kidney : A randomized, double-blind, placebo-controlled, phase 2 study</article-title>. <source>Cancer</source> <volume>118</volume>: <fpage>6152</fpage>–<lpage>6161</lpage>.</mixed-citation>
</ref>
<ref id="pone.0090135-Hainsworth1"><label>57</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Hainsworth</surname><given-names>JD</given-names></name>, <name name-style="western"><surname>Rubin</surname><given-names>MS</given-names></name>, <name name-style="western"><surname>Arrowsmith</surname><given-names>ER</given-names></name>, <name name-style="western"><surname>Khatcheressian</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Crane</surname><given-names>EJ</given-names></name>, <etal>et al</etal>. (<year>2013</year>) <article-title>Pazopanib as Second-Line Treatment After Sunitinib or Bevacizumab in Patients With Advanced Renal Cell Carcinoma: A Sarah Cannon Oncology Research Consortium Phase II Trial</article-title>. <source>Clin Genitourin Cancer</source> <volume>11</volume>: <fpage>270</fpage>–<lpage>275</lpage>.</mixed-citation>
</ref>
<ref id="pone.0090135-Motzer3"><label>58</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Motzer</surname><given-names>RJ</given-names></name>, <name name-style="western"><surname>Escudier</surname><given-names>B</given-names></name>, <name name-style="western"><surname>Tomczak</surname><given-names>P</given-names></name>, <name name-style="western"><surname>Hutson</surname><given-names>TE</given-names></name>, <name name-style="western"><surname>Michaelson</surname><given-names>MD</given-names></name>, <etal>et al</etal>. (<year>2013</year>) <article-title>Axitinib versus sorafenib as second-line treatment for advanced renal cell carcinoma: overall survival analysis and updated results from a randomised phase 3 trial</article-title>. <source>Lancet Oncol</source> <volume>14</volume>: <fpage>552</fpage>–<lpage>562</lpage>.</mixed-citation>
</ref>
<ref id="pone.0090135-Sternberg2"><label>59</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Sternberg</surname><given-names>CN</given-names></name>, <name name-style="western"><surname>Hawkins</surname><given-names>RE</given-names></name>, <name name-style="western"><surname>Wagstaff</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Salman</surname><given-names>P</given-names></name>, <name name-style="western"><surname>Mardiak</surname><given-names>J</given-names></name>, <etal>et al</etal>. (<year>2013</year>) <article-title>A randomised, double-blind phase III study of pazopanib in patients with advanced and/or metastatic renal cell carcinoma: final overall survival results and safety update</article-title>. <source>Eur J Cancer</source> <volume>49</volume>: <fpage>1287</fpage>–<lpage>1296</lpage>.</mixed-citation>
</ref>
<ref id="pone.0090135-Bible1"><label>60</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Bible</surname><given-names>KC</given-names></name>, <name name-style="western"><surname>Suman</surname><given-names>VJ</given-names></name>, <name name-style="western"><surname>Molina</surname><given-names>JR</given-names></name>, <name name-style="western"><surname>Smallridge</surname><given-names>RC</given-names></name>, <name name-style="western"><surname>Maples</surname><given-names>WJ</given-names></name>, <etal>et al</etal>. (<year>2010</year>) <article-title>Efficacy of pazopanib in progressive, radioiodine-refractory, metastatic differentiated thyroid cancers: results of a phase 2 consortium study</article-title>. <source>Lancet Oncol</source> <volume>11</volume>: <fpage>962</fpage>–<lpage>972</lpage>.</mixed-citation>
</ref>
<ref id="pone.0090135-Cohen1"><label>61</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Cohen</surname><given-names>EE</given-names></name>, <name name-style="western"><surname>Rosen</surname><given-names>LS</given-names></name>, <name name-style="western"><surname>Vokes</surname><given-names>EE</given-names></name>, <name name-style="western"><surname>Kies</surname><given-names>MS</given-names></name>, <name name-style="western"><surname>Forastiere</surname><given-names>AA</given-names></name>, <etal>et al</etal>. (<year>2008</year>) <article-title>Axitinib is an active treatment for all histologic subtypes of advanced thyroid cancer: results from a phase II study</article-title>. <source>J Clin Oncol</source> <volume>26</volume>: <fpage>4708</fpage>–<lpage>4713</lpage>.</mixed-citation>
</ref>
<ref id="pone.0090135-Wells2"><label>62</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Wells</surname><given-names>SA</given-names><suffix>Jr</suffix></name>, <name name-style="western"><surname>Robinson</surname><given-names>BG</given-names></name>, <name name-style="western"><surname>Gagel</surname><given-names>RF</given-names></name>, <name name-style="western"><surname>Dralle</surname><given-names>H</given-names></name>, <name name-style="western"><surname>Fagin</surname><given-names>JA</given-names></name>, <etal>et al</etal>. (<year>2012</year>) <article-title>Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: a randomized, double-blind phase III trial</article-title>. <source>J Clin Oncol</source> <volume>30</volume>: <fpage>134</fpage>–<lpage>141</lpage>.</mixed-citation>
</ref>
<ref id="pone.0090135-Spano1"><label>63</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Spano</surname><given-names>JP</given-names></name>, <name name-style="western"><surname>Chodkiewicz</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Maurel</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Wong</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Wasan</surname><given-names>H</given-names></name>, <etal>et al</etal>. (<year>2008</year>) <article-title>Efficacy of gemcitabine plus axitinib compared with gemcitabine alone in patients with advanced pancreatic cancer: an open-label randomised phase II study</article-title>. <source>Lancet</source> <volume>371</volume>: <fpage>2101</fpage>–<lpage>2108</lpage>.</mixed-citation>
</ref>
<ref id="pone.0090135-Kindler1"><label>64</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Kindler</surname><given-names>HL</given-names></name>, <name name-style="western"><surname>Wroblewski</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Wallace</surname><given-names>JA</given-names></name>, <name name-style="western"><surname>Hall</surname><given-names>MJ</given-names></name>, <name name-style="western"><surname>Locker</surname><given-names>G</given-names></name>, <etal>et al</etal>. (<year>2012</year>) <article-title>Gemcitabine plus sorafenib in patients with advanced pancreatic cancer: a phase II trial of the University of Chicago Phase II Consortium</article-title>. <source>Invest New Drugs</source> <volume>30</volume>: <fpage>382</fpage>–<lpage>386</lpage>.</mixed-citation>
</ref>
<ref id="pone.0090135-Sleijfer1"><label>65</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Sleijfer</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Ray-Coquard</surname><given-names>I</given-names></name>, <name name-style="western"><surname>Papai</surname><given-names>Z</given-names></name>, <name name-style="western"><surname>Le Cesne</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Scurr</surname><given-names>M</given-names></name>, <etal>et al</etal>. (<year>2009</year>) <article-title>Pazopanib, a Multikinase Angiogenesis Inhibitor, in Patients With Relapsed or Refractory Advanced Soft Tissue Sarcoma: A Phase II Study From the European Organisation for Research and Treatment of Cancer-Soft Tissue and Bone Sarcoma Group (EORTC Study 62043)</article-title>. <source>JOURNAL OF CLINICAL ONCOLOGY</source> <volume>27</volume>: <fpage>3126</fpage>–<lpage>3132</lpage>.</mixed-citation>
</ref>
<ref id="pone.0090135-vanderGraaf1"><label>66</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>van der Graaf</surname><given-names>WT</given-names></name>, <name name-style="western"><surname>Blay</surname><given-names>JY</given-names></name>, <name name-style="western"><surname>Chawla</surname><given-names>SP</given-names></name>, <name name-style="western"><surname>Kim</surname><given-names>DW</given-names></name>, <name name-style="western"><surname>Bui-Nguyen</surname><given-names>B</given-names></name>, <etal>et al</etal>. (<year>2012</year>) <article-title>Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial</article-title>. <source>Lancet</source> <volume>379</volume>: <fpage>1879</fpage>–<lpage>1886</lpage>.</mixed-citation>
</ref>
<ref id="pone.0090135-Batchelor1"><label>67</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Batchelor</surname><given-names>TT</given-names></name>, <name name-style="western"><surname>Duda</surname><given-names>DG</given-names></name>, <name name-style="western"><surname>di Tomaso</surname><given-names>E</given-names></name>, <name name-style="western"><surname>Ancukiewicz</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Plotkin</surname><given-names>SR</given-names></name>, <etal>et al</etal>. (<year>2010</year>) <article-title>Phase II study of cediranib, an oral pan-vascular endothelial growth factor receptor tyrosine kinase inhibitor, in patients with recurrent glioblastoma</article-title>. <source>J Clin Oncol</source> <volume>28</volume>: <fpage>2817</fpage>–<lpage>2823</lpage>.</mixed-citation>
</ref>
<ref id="pone.0090135-Iwamoto1"><label>68</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Iwamoto</surname><given-names>FM</given-names></name>, <name name-style="western"><surname>Lamborn</surname><given-names>KR</given-names></name>, <name name-style="western"><surname>Robins</surname><given-names>HI</given-names></name>, <name name-style="western"><surname>Mehta</surname><given-names>MP</given-names></name>, <name name-style="western"><surname>Chang</surname><given-names>SM</given-names></name>, <etal>et al</etal>. (<year>2010</year>) <article-title>Phase II trial of pazopanib (GW786034), an oral multi-targeted angiogenesis inhibitor, for adults with recurrent glioblastoma (North American Brain Tumor Consortium Study 06-02)</article-title>. <source>Neuro Oncol</source> <volume>12</volume>: <fpage>855</fpage>–<lpage>861</lpage>.</mixed-citation>
</ref>
<ref id="pone.0090135-Toh1"><label>69</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Toh</surname><given-names>HC</given-names></name>, <name name-style="western"><surname>Chen</surname><given-names>PJ</given-names></name>, <name name-style="western"><surname>Carr</surname><given-names>BI</given-names></name>, <name name-style="western"><surname>Knox</surname><given-names>JJ</given-names></name>, <name name-style="western"><surname>Gill</surname><given-names>S</given-names></name>, <etal>et al</etal>. (<year>2013</year>) <article-title>Phase 2 trial of linifanib (ABT-869) in patients with unresectable or metastatic hepatocellular carcinoma</article-title>. <source>Cancer</source> <volume>119</volume>: <fpage>380</fpage>–<lpage>387</lpage>.</mixed-citation>
</ref>
<ref id="pone.0090135-Ramalingam1"><label>70</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Ramalingam</surname><given-names>SS</given-names></name>, <name name-style="western"><surname>Belani</surname><given-names>CP</given-names></name>, <name name-style="western"><surname>Mack</surname><given-names>PC</given-names></name>, <name name-style="western"><surname>Vokes</surname><given-names>EE</given-names></name>, <name name-style="western"><surname>Longmate</surname><given-names>J</given-names></name>, <etal>et al</etal>. (<year>2010</year>) <article-title>Phase II study of Cediranib (AZD 2171), an inhibitor of the vascular endothelial growth factor receptor, for second-line therapy of small cell lung cancer (National Cancer Institute #7097)</article-title>. <source>J Thorac Oncol</source> <volume>5</volume>: <fpage>1279</fpage>–<lpage>1284</lpage>.</mixed-citation>
</ref>
<ref id="pone.0090135-Robinson1"><label>71</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Robinson</surname><given-names>ES</given-names></name>, <name name-style="western"><surname>Matulonis</surname><given-names>UA</given-names></name>, <name name-style="western"><surname>Ivy</surname><given-names>P</given-names></name>, <name name-style="western"><surname>Berlin</surname><given-names>ST</given-names></name>, <name name-style="western"><surname>Tyburski</surname><given-names>K</given-names></name>, <etal>et al</etal>. (<year>2010</year>) <article-title>Rapid development of hypertension and proteinuria with cediranib, an oral vascular endothelial growth factor receptor inhibitor</article-title>. <source>Clin J Am Soc Nephrol</source> <volume>5</volume>: <fpage>477</fpage>–<lpage>483</lpage>.</mixed-citation>
</ref>
<ref id="pone.0090135-Lim1"><label>72</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Lim</surname><given-names>WT</given-names></name>, <name name-style="western"><surname>Ng</surname><given-names>QS</given-names></name>, <name name-style="western"><surname>Ivy</surname><given-names>P</given-names></name>, <name name-style="western"><surname>Leong</surname><given-names>SS</given-names></name>, <name name-style="western"><surname>Singh</surname><given-names>O</given-names></name>, <etal>et al</etal>. (<year>2011</year>) <article-title>A Phase II Study of Pazopanib in Asian Patients with Recurrent/Metastatic Nasopharyngeal Carcinoma</article-title>. <source>Clinical cancer research</source> <volume>17</volume>: <fpage>5481</fpage>–<lpage>5489</lpage>.</mixed-citation>
</ref>
<ref id="pone.0090135-Tan1"><label>73</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Tan</surname><given-names>EH</given-names></name>, <name name-style="western"><surname>Goss</surname><given-names>GD</given-names></name>, <name name-style="western"><surname>Salgia</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Besse</surname><given-names>B</given-names></name>, <name name-style="western"><surname>Gandara</surname><given-names>DR</given-names></name>, <etal>et al</etal>. (<year>2011</year>) <article-title>Phase 2 trial of Linifanib (ABT-869) in patients with advanced non-small cell lung cancer</article-title>. <source>J Thorac Oncol</source> <volume>6</volume>: <fpage>1418</fpage>–<lpage>1425</lpage>.</mixed-citation>
</ref>
<ref id="pone.0090135-Campbell1"><label>74</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Campbell</surname><given-names>NP</given-names></name>, <name name-style="western"><surname>Kunnavakkam</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Leighl</surname><given-names>N</given-names></name>, <name name-style="western"><surname>Vincent</surname><given-names>MD</given-names></name>, <name name-style="western"><surname>Gandara</surname><given-names>DR</given-names></name>, <etal>et al</etal>. (<year>2012</year>) <article-title>Cediranib in patients with malignant mesothelioma: a phase II trial of the University of Chicago Phase II Consortium</article-title>. <source>Lung Cancer</source> <volume>78</volume>: <fpage>76</fpage>–<lpage>80</lpage>.</mixed-citation>
</ref>
<ref id="pone.0090135-Kummar1"><label>75</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Kummar</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Allen</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Monks</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Polley</surname><given-names>EC</given-names></name>, <name name-style="western"><surname>Hose</surname><given-names>CD</given-names></name>, <etal>et al</etal>. (<year>2013</year>) <article-title>Cediranib for Metastatic Alveolar Soft Part Sarcoma</article-title>. <source>J Clin Oncol 2013</source> <volume>31</volume>: <fpage>2296</fpage>–<lpage>2302</lpage>.</mixed-citation>
</ref>
<ref id="pone.0090135-Schmoll1"><label>76</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Schmoll</surname><given-names>HJ</given-names></name>, <name name-style="western"><surname>Cunningham</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Sobrero</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Karapetis</surname><given-names>CS</given-names></name>, <name name-style="western"><surname>Rougier</surname><given-names>P</given-names></name>, <etal>et al</etal>. (<year>2012</year>) <article-title>Cediranib with mFOLFOX6 versus bevacizumab with mFOLFOX6 as first-line treatment for patients with advanced colorectal cancer: a double-blind, randomized phase III study (HORIZON III)</article-title>. <source>J Clin Oncol</source> <volume>30</volume>: <fpage>3588</fpage>–<lpage>3595</lpage>.</mixed-citation>
</ref>
<ref id="pone.0090135-Cunningham1"><label>77</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Cunningham</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Wong</surname><given-names>RP</given-names></name>, <name name-style="western"><surname>D'Haens</surname><given-names>G</given-names></name>, <name name-style="western"><surname>Douillard</surname><given-names>JY</given-names></name>, <name name-style="western"><surname>Robertson</surname><given-names>J</given-names></name>, <etal>et al</etal>. (<year>2013</year>) <article-title>Cediranib with mFOLFOX6 vs bevacizumab with mFOLFOX6 in previously treated metastatic colorectal cancer</article-title>. <source>Br J Cancer</source> <volume>108</volume>: <fpage>493</fpage>–<lpage>502</lpage>.</mixed-citation>
</ref>
<ref id="pone.0090135-Grothey1"><label>78</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Grothey</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Van Cutsem</surname><given-names>E</given-names></name>, <name name-style="western"><surname>Sobrero</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Siena</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Falcone</surname><given-names>A</given-names></name>, <etal>et al</etal>. (<year>2013</year>) <article-title>Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial</article-title>. <source>Lancet</source> <volume>381</volume>: <fpage>303</fpage>–<lpage>312</lpage>.</mixed-citation>
</ref>
<ref id="pone.0090135-Infante1"><label>79</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Infante</surname><given-names>JR</given-names></name>, <name name-style="western"><surname>Reid</surname><given-names>TR</given-names></name>, <name name-style="western"><surname>Cohn</surname><given-names>AL</given-names></name>, <name name-style="western"><surname>Edenfield</surname><given-names>WJ</given-names></name>, <name name-style="western"><surname>Cescon</surname><given-names>TP</given-names></name>, <etal>et al</etal>. (<year>2013</year>) <article-title>Axitinib and/or bevacizumab with modified FOLFOX-6 as first-line therapy for metastatic colorectal cancer: A randomized phase 2 study</article-title>. <source>Cancer</source> <volume>119</volume>: <fpage>2555</fpage>–<lpage>2563</lpage>.</mixed-citation>
</ref>
<ref id="pone.0090135-Eremina1"><label>80</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Eremina</surname><given-names>V</given-names></name>, <name name-style="western"><surname>Sood</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Haigh</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Nagy</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Lajoie</surname><given-names>G</given-names></name>, <etal>et al</etal>. (<year>2003</year>) <article-title>Glomerular-specific alterations of VEGF-A expression lead to distinct congenital and acquired renal diseases</article-title>. <source>J Clin Invest</source> <volume>111</volume>: <fpage>707</fpage>–<lpage>716</lpage>.</mixed-citation>
</ref>
<ref id="pone.0090135-Schrijvers1"><label>81</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Schrijvers</surname><given-names>BF</given-names></name>, <name name-style="western"><surname>Flyvbjerg</surname><given-names>A</given-names></name>, <name name-style="western"><surname>De Vriese</surname><given-names>AS</given-names></name> (<year>2004</year>) <article-title>The role of vascular endothelial growth factor (VEGF) in renal pathophysiology</article-title>. <source>Kidney Int</source> <volume>65</volume>: <fpage>2003</fpage>–<lpage>2017</lpage>.</mixed-citation>
</ref>
<ref id="pone.0090135-Vuorela1"><label>82</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Vuorela</surname><given-names>P</given-names></name>, <name name-style="western"><surname>Helske</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Hornig</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Alitalo</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Weich</surname><given-names>H</given-names></name>, <etal>et al</etal>. (<year>2000</year>) <article-title>Amniotic fluid–soluble vascular endothelial growth factor receptor-1 in preeclampsia</article-title>. <source>Obstet Gynecol</source> <volume>95</volume>: <fpage>353</fpage>–<lpage>357</lpage>.</mixed-citation>
</ref>
<ref id="pone.0090135-KincaidSmith1"><label>83</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Kincaid-Smith</surname><given-names>P</given-names></name> (<year>1991</year>) <article-title>The renal lesion of preeclampsia revisited</article-title>. <source>Am J Kidney Dis</source> <volume>17</volume>: <fpage>144</fpage>–<lpage>148</lpage>.</mixed-citation>
</ref>
<ref id="pone.0090135-Eremina2"><label>84</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Eremina</surname><given-names>V</given-names></name>, <name name-style="western"><surname>Jefferson</surname><given-names>JA</given-names></name>, <name name-style="western"><surname>Kowalewska</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Hochster</surname><given-names>H</given-names></name>, <name name-style="western"><surname>Haas</surname><given-names>M</given-names></name>, <etal>et al</etal>. (<year>2008</year>) <article-title>VEGF inhibition and renal thrombotic microangiopathy</article-title>. <source>N Engl J Med</source> <volume>358</volume>: <fpage>1129</fpage>–<lpage>1136</lpage>.</mixed-citation>
</ref>
<ref id="pone.0090135-US1"><label>85</label>
<mixed-citation publication-type="other" xlink:type="simple">U.S. Food and Drug Administration. FDA Briefing Document, Oncologic Drugs Advisory Committee Meeting, NDA 20324 Axitinib (Inlyta). <ext-link ext-link-type="uri" xlink:href="http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/202324lbl.pdf" xlink:type="simple">http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/202324lbl.pdf</ext-link> assessed Jun 11, 2013</mixed-citation>
</ref>
<ref id="pone.0090135-US2"><label>86</label>
<mixed-citation publication-type="other" xlink:type="simple">US Food and Drug Administration. Highlights of Prescribing Information. Votrient (pazopanib) tablets. Available: <ext-link ext-link-type="uri" xlink:href="http://wwwaccessdatafdagov/drugsatfda_docs/label/2009/022465lblpdf" xlink:type="simple">http://wwwaccessdatafdagov/drugsatfda_docs/label/2009/022465lblpdf</ext-link> Accessed 2013 June 11.</mixed-citation>
</ref>
<ref id="pone.0090135-1"><label>87</label>
<mixed-citation publication-type="journal" xlink:type="simple"><article-title>K/DOQI clinical practice guidelines on hypertension and antihypertensive agents in chronic kidney disease</article-title>. <source>Am J Kidney Dis</source> <volume>43</volume>: <fpage>S1</fpage>–<lpage>290</lpage>.</mixed-citation>
</ref>
</ref-list></back>
</article>